C O N FI D E N TI A L
Pa ge 1 of 9 6C LI NI C A L S T U D Y P R O T O C O L
P R O T O C O L N U M B E R: 4 3 Q M 1 9 0 2
C O N FI D E N TI A L
T his d oc u me nt c o nt ai ns c o nfi de nti al, pr o priet ar y i nf or m ati o n
All t he i nf or mati o n pr o vi de d t o t he I n vesti gat or a n d his/ her staff a n d all data o btai ne d t hr o u g h t his 
Q- Me d A B cli nical st u d y pr ot oc ol are c o nfi de ntial.  Q-Me d A B is t he o w ner of all i nf or mati o n 
i ncl u de d i n t his pr ot oc ol as S p o ns or a n d t he S p o ns or reser ves all pr o prietar y ri g hts. N o i nf or mati o n 
ma y  be discl ose d t o a n y thir d part y  wit h o ut pri or writte n c o nse nt fr o m 
Q- Me d A B.Title  D o c i d  
[ADDRESS_1103351] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103352] u d y t o E val uate 
t he Efficac y a n d Safet y of Q M 1 1 1 4-D P f or t he Treat me nt of M o derate t o Se vere 
Lateral Ca nt hal Li nes a n d Gla bellar Li nes Al o ne or i n C o m bi nati o n
( R E A D Y – 3)
C li nic al Tri al N u m ber ( CT N ): 4 3 Q M 1 9 0 2
I N D N u m ber: 1 1 0 1 9 6
S P O N S O R:
Na me: Q- Me d A B, a Gal der ma affiliate
A d dress: Se mi narie gata n 2 1
S E - 7 5 2 2 8 U p psala, S we de n
P h o ne: + 4 6 1 8 4 7 4 9 0 0 0
C O N T R A C T R E S E A R C H O R G A NI Z A TI O N ( C R O):
Na me:
A d dress:
P h o ne:
S A F E T Y:
F or safet y q uesti o ns, please c o ntact t he Safet y e-mail or Me dical M o nit or usi n g t he details pr o vi de d 
i n Secti o n 1 1. 9 . Seri o us a d verse e ve nts ( S A Es) a n d pre g na nc y  re p ort f or ms s h o ul d be s u b mitte d as 
desc ri be d i n Secti o ns 7. 2. 6. 2. 2 a n d 7. 2. 6. 2. 3 .
M E DI C A L M O NI T O R:
F or a n y me dical q uesti o ns relate d t o t he cli nical st u d y pr ot oc ol, please c o ntact t he Me dical M o nit or 
usi n g t he details pr o vi de d i n Secti o n [ADDRESS_1103353] u d y shall be perf or me d i n c o m plia nce wit h t he cli nical trial a gree me nt ( C T A), t he 
cli nical st u d y pr ot oc ol ( C S P), I CH -G o o d Cli nical Practice ( G C P),1a n d a p plica ble re gi o nal a n d 
n ati o nal re g ulati o ns. T he st u d y shall be c o n d ucte d i n acc or da nce wit h t he et hical pri nci ples t hat ha ve 
t heir ori gi n i n t he Declarati o n of Helsi n ki (htt ps:// w w w. w ma. net/ p olicies- p ost/ w ma -declarati o n -of-
helsi n ki -et hical-pri nci ples -f or-me dical -researc h-i n v ol vin g- h u ma n -s u bjects/).Title  D o c i d  
[ADDRESS_1103354] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103355] u g Pr ofile ..............................................................................................................................2 6
1. 2. 2 Pre -Cli nic al D oc u me nt ati o n .................................................................................................... 2 6
1. 2. 3 Cli nic al D oc u me nt ati o n ........................................................................................................... 2 7
1. 2. 4 D ose R ati o n ale .......................................................................................................................... 3 0
1. 3 Ris k/ Be n efit Assess me nt ............................................................................................................... [ADDRESS_1103356] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C CI
C O N FI D E N TI A L
Pa ge 4 of 9 65. 4 Pre vi o us a n d C o nc o mit a nt T her a pi[INVESTIGATOR_014] ......................................................................................... 3 9
5. 4. 1 Defi niti o n .................................................................................................................................. 3 9
5. 4. 2 C ate g ories ................................................................................................................................. 3 9
5. 4. 3 Rec or di n g .................................................................................................................................. 3 9
5. 4. 4 A ut h orize d C o nc o mit a nt T her a pi[INVESTIGATOR_014] ....................................................................................... 3 9
5. 4. 5 Pr o hi bite d C o nc o mit a nt T her a pi[INVESTIGATOR_014] ........................................................................................ 4 0
5. 5 Pr oce d ures/ Re as o ns f or S u bject Disc o nti n u ati o n ...................................................................... [ADDRESS_1103357] I de ntific ati o n N u m ber ( SI N) ..................................................................................... 4 3
6. 1. 5 Met h o d of Tre at me nt Assi g n me nt .......................................................................................... 4 4
6. 1. 6 Kit N u m ber/ R a n d o miz ati o n N u m ber .................................................................................... [ADDRESS_1103358] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103359] u d y ................................................................................... 4 9
7. C LI NI C A L S T U D Y A S S E S S M E N T ........................................................................................... 4 9
7. 1 Effic ac y Assess me nts ..................................................................................................................... 4 9
7. 1. 1 I n vesti g at or 4-p oi nt P h ot o gr a p hic Sc ale of L ater al C a nt h al Li ne Se verit y  
( L C L-I L A) ................................................................................................................................ [ADDRESS_1103360] 4 -p oi nt P h ot o gr a p hic Sc ale of L ater al C a nt h al Li ne Se verit y ( L C L -
S L A) .......................................................................................................................................... 5 0
7. 1. 3 I n vesti g at or 4-p oi nt P h ot o gr a p hic Sc ale of Gl a bell ar Li ne Se verit y ( G L -I L A) ................. [ADDRESS_1103361] atic 4 -p oi nt C ate g oric al Sc ale of Gl a bell ar Li ne Se verit y ( G L -S L A) ................ 5 0
7. 2 S afet y Assess me nts ........................................................................................................................ 5 2
7. 2. 1 F oc use d P h ysic al E x a mi n ati o n ( F P E) .................................................................................... 5 2
7. 2. 2 Vit al Si g ns ................................................................................................................................. 5 2
7. 2. 3 Electr oc ar di o gr a m ( E C G) ....................................................................................................... 5 3
7. 2. 4 L a b or at or y S afet y Tests .......................................................................................................... 5 3
7. 2. 5 Ne utr alizi n g A nti b o d y Testi n g ................................................................................................ 5 4
7. 2. 6 A d verse E ve nts ......................................................................................................................... 5 4
7. 2. 6. 1 Defi niti o ns ............................................................................................................................ 5 4
7. 2. 6. 1. 1 A dverse Eve nts ( A E) ........................................................................................................ 5 4
7. 2. 6. 1. 2 Tre at me nt E mer ge nt A dverse Eve nt ( T E A E) ................................................................... 5 5
7. 2. 6. 1. 3 Seri o us A dverse Eve nts ( S A E) ......................................................................................... [ADDRESS_1103362] a n d/ or Cli nic al St u dy Pr oce d ure.............................. [ADDRESS_1103363] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103364] u d y Visits ............................................................................................. 6 0
8. 1. 1 Scree ni n g/ Visit 1 ( -1 4 d a ys t o D a y 0) ...................................................................................... 6 0
8. 1. 2 B aseli ne/ Visit 2 [ D a y 0] ............................................................................................................ 6 2
8. 1. 3 D a y 7/ Visit 3 ( ± 1 d a y) .............................................................................................................. 6 3
8. 1. 4 D a y 1 4/ Visit 4 ( ± 3 d a ys) ........................................................................................................... 6 4
8. 1. 5 M o nt h 1/ Visit 5 ( ± 5 d a ys) ........................................................................................................ 6 5
8. 1. 6 M o nt hs 2 -5/ Visit 6 -9 ( ± 5 d a ys) ................................................................................................ 6 6
8. 1. 7 M o nt h 6/ Visit 1 0 or E arl y Ter mi n ati o n visit ( ± 5 d a ys) ........................................................ [ADDRESS_1103365] a ns ................................................................................................... 6 8
9. 1. 1 D at a Tr a nsf or m ati o ns ............................................................................................................. 6 8
9. 1. 2 P o p ul ati o ns A n al yze d a n d E v al u a bilit y ................................................................................. 6 8
9. 1. 2. 1 M o difie d I nte nt -t o-tre at ( mI T T) Effic ac y P o p ul ati o n..................................................... 6 8
9. 1. 2. 2 I nte nt-t o-tre at (I T T) Effic ac y P o p ul ati o n......................................................................... 6 9
9. 1. 2. 3 Per -pr ot oc ol ( P P) Effic ac y P o p ul ati o n .............................................................................. [ADDRESS_1103366] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103367] oric al D at a ......................................................................................................................... 7 1
9. 2. 2 Ass u m pti o ns ................................................................ ............................................................. 7 2
9. 2. 3 S a m ple Size C alc ul ati o n .......................................................................................................... 7 3
9. 2. 4 I nteri m A n al ysis ....................................................................................................................... 7 3
1 0. T R AI NI N G / M O NI T O RI N G / D A T A M A N A G E M E N T / Q U A LI T Y 
A S S U R A N C E ................................................................................................................................ 7 3
1 0. 1 Pers o n nel Tr ai ni n g ........................................................................................................................ 7 3
1 0. 2 Cli nic al M o nit ori n g ....................................................................................................................... 7 3
1 0. 3 D at a M a n a ge me nt ................................................................ ......................................................... 7 3
1 0. 4 Q u alit y Ass ur a nce/ A u dit/I ns pecti o n ........................................................................................... [ADDRESS_1103368]/ A me n d me nts ..................................................................... [ADDRESS_1103369] ............................................................................................................ 7 4
1 0. 5. 2 A me n d me nts ............................................................................................................................. 7 5
1 1. E T HI C S A N D G E N E R A L C LI NI C A L S T U D Y C O N D U C T C O N SI D E R A TI O N S ............. 7 5
1 1. 1 I n de pe n de nt Et hics C o m mittee (I E C) or I nstit uti o n al Re vie w B o ar d (I R B) .......................... [ADDRESS_1103370] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103371] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103372] u d y  Titl e: A M ulti c e nt er, R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o -C o ntr oll e d St u d y t o E v al u at e t h e Effi c a c y 
a n d S af et y of Q M 1 1 1 4 -D P f or t h e Tr e at m e nt of M o d er at e t o S e v er e L at er al C a nt h al Li n e s ( L C L) a n d Gl a b ell ar Li n e s 
( G L) Al o n e or i n C o m bi n ati o n ( R E A D Y – 3)
S h ort Titl e : Q M [ADDRESS_1103373] u d y  P o p ul ati o n: M al e a n d f e m al e s u bj e ct s, 1 8 y e ar s of a g e a n d ol d er, wit h m o d er at e t o 
s e v er e l at er al l at er al c a nt h al li n e s (L C L ) at m a xi m u m s mil e a n d m o d er at e t o 
s e v er e gl a b ell ar li n e s (G L ) at m a xi m u m fr o w n.
Cli ni c al St u d y  D e si g n: T hi s i s a p h a s e 3, m ulti c e nt er, r a n d o mi z e d, d o u bl e -bli n d, pl a c e b o -c o ntr oll e d, 
p ar all el -gr o u p, U S st u d y wit h tr e at m e nt of Q M [ADDRESS_1103374] s 
will b e r a n d o ml y a s si g n e d t o tr e at m e nt i n a 2: 2: 2: [ADDRESS_1103375] s will r e c ei v e 
a si n gl e tr e at m e nt at b a s eli n e ( D a y 0) of eit h er :
 6 0 u nit s Q M 1 1 1 4 -D P ( [ADDRESS_1103376] s) ,
 5 0 u nit s Q M 1 1 1 4 - D P ( [ADDRESS_1103377] s) ,
 1 1 0 u nit s Q M 1 1 1 4 - D P ( [ADDRESS_1103378] s) , or
 Pl a c e b o i n b ot h t h e L C L a n d G L ( [ADDRESS_1103379] s) .
R a n d o mi z ati o n will b e str atifi e d b y st u d y c e nt e r.
S u bj e ct s eli gi bl e f or t h e tr e at m e nt m u st m e et t h e s e v erit y crit eri a f or L C L a n d 
G L at b a s eli n e (i. e. m o d er at e t o s e v er e L C L a n d G L at m a xi m u m s mil e a n d 
m a xi m u m fr o w n, r e s p e cti v el y). L C L s h o ul d b e bil at er all y s y m m etri c al. 
B a s eli n e wri n kl e s e v erit y d et er mi n ati o n will b e b a s e d o n b ot h i n v e sti g at or 
a n d s u bj e ct r ati n g s u si n g t h e 4- p oi nt p h ot o gr a p hi c s c al e of L C L s e v erit y 
( L C L-I L A; L C L-S L A) a n d t h e 4 -p oi nt p h ot o gr a p hi c s c al e of G L s e v erit y ( G L -
I L A) a n d t h e s u bj e ct 4-p oi nt c at e g ori c al s c al e ( G L -S L A).
F oll o wi n g tr e at m e nt at b a s eli n e, s u bj e ct s will b e m o nit or e d f or effi c a c y a n d 
s af et y o v er a p eri o d of 6 m o nt h s.   
T ar g et I n di c ati o n: T hi s st u d y i s d e si g n e d t o e v al u at e t h e s af et y a n d effi c a c y of Q M [ADDRESS_1103380] s ( Pl a n n e d): A p pr o xi m at el y [ADDRESS_1103381] s will b e e nr oll e d.
N u m b er of C li ni c al S t u d y C e nt er s 
( Pl a n n e d):U p t o 1 5 c e nt er s
R e gi o n( s) / C o u ntr y (i e s) In v ol v e d 
( Pl a n n e d):U S a n d C a n a d a
Cli ni c al S t u d y D ur ati o n: T h e pl a n n e d d ur ati o n of r e cr uit m e nt (fr o m fir st s u bj e ct fir st vi sit [ F S F V] t o l a st 
s u bj e ct fir st vi sit [ L S F V]) i s a p pr o xi m at el y [ADDRESS_1103382] vi sit (L S L V) 
i s a p pr o xi m at el y 9. [ADDRESS_1103383] P arti ci p ati o n: Cli ni c al st u d y p arti ci p ati o n f or e a c h s u bj e ct i s a p pr o xi m at el y [ADDRESS_1103384] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103385] u d y  Titl e: A M ulti c e nt er, R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o -C o ntr oll e d St u d y t o E v al u at e t h e Effi c a c y 
a n d S af et y of Q M 1 1 1 4 -D P f or t h e Tr e at m e nt of M o d er at e t o S e v er e L at er al C a nt h al Li n e s ( L C L) a n d Gl a b ell ar Li n e s 
( G L) Al o n e or i n C o m bi n ati o n ( R E A D Y – 3)
K e y I n cl u si o n Crit eri a: 1. M al e or f e m al e 1 8 y e ar s of a g e or ol d er .
2. M o d er at e t o s e v er e bil at er all y s y m m etri c al L C L ( gr a d e 2 or 3 o n t h e 4 -
p oi nt P h ot o gr a p hi c S c al e r a n gi n g fr o m 0 [ n o n e] t o 3 [ s e v er e]) at 
m a xi m u m s mil e a s a s s e s s e d b y t h e I n v e sti g at or li v e a s s e s s m e nt ( L C L -
I L A).
3. B il at er all y s y m m etri c al L C L gr a d e d a s L e v el 2 or L e v el 3 o n t h e 4 -p oi nt 
P h ot o gr a p hi c S c al e (r a n gi n g fr o m L e v el 0 t o L e v el 3) at m a xi m u m s mil e 
a s a s s e s s e d b y t h e s u bj e ct li v e a s s e s s m e nt ( L C L -S L A).
4. M o d er at e t o s e v er e G L ( gr a d e 2 or 3 o n t h e 4- p oi nt P h ot o gr a p hi c S c al e 
r a n gi n g fr o m 0 [ n o n e] t o 3 [ s e v er e]) at m a xi m u m fr o w n a s a s s e s s e d b y 
t h e I n v e sti g at or ( G L-I L A).
5. M o d er at e t o s e v er e G L (gr a d e [ADDRESS_1103386] ati c 4- P oi nt C at e g ori c al 
S c al e r a n gi n g fr o m 0 [ no wri n kl e s ] t o 3 [ s e v er e wri n kl e s ]) at m a xi m u m 
fr o w n a s a s s e s s e d b y t h e s u bj e ct ( G L-S L A).
6. F e m al e of n o n -c hil d b e ari n g p ot e nti al (i. e., p o st -m e n o p a u s al [ ab s e n c e 
of m e n str u al bl e e di n g f or 1 y e ar pri or t o s cr e e ni n g, wit h o ut a n y ot h er 
m e di c al r e a s o n], or h a s u n d er g o n e h y st er e ct o m y or bil at er al 
o o p h or e ct o m y).
O R
F e m al e of c hil d b e ari n g p ot e nti al wit h a n e g ati v e uri n e pr e g n a n c y t e st at 
s cr e e ni n g a n d b a s eli n e a n d a gr e e s t o u s e a hi g hl y eff e cti v e a n d 
a p pr o v e d c o ntr a c e pti v e m et h o d f or t h e d ur ati o n of t h e st u d y. A hi g hl y 
eff e cti v e m et h o d of c o ntr a c e pti o n i s d efi n e d a s:
 Bil at er al t u b al li g ati o n;
 C o m bi n e d  ( e str o g e n a n d pr o g e st er o n e c o nt ai ni n g) or al, 
i ntr a v a gi n al or tr a n s d er m al c o ntr a c e pti v e s t h at i n hi bit o v ul ati o n a s 
t h e pri m ar y m o d e of a cti o n, o n a st a bl e d o s e f or at l e a st 2 8 d a y s 
pri or t o s cr e e ni n g vi sit;
 I ntr a ut eri n e d e vi c e (I U D) i n s ert e d at l e a st 2 8 d a y s pri or t o 
s cr e e ni n g vi sit; 
 I ntr a ut eri n e h or m o n e-r el e a si n g s y st e m;
 P art n er v a s e ct o mi z e d f or at l e a st t hr e e m o nt h s pri or t o s cr e e ni n g 
vi sit;
 Pr o g e st o g e n -o nl y or al, i nj e ct a bl e or i m pl a nt a bl e c o ntr a c e pti v e s t h at 
i n hi bit o v ul ati o n a s t h e pri m ar y m o d e of a cti o n, o n a st a bl e d o s e f or 
at l e a st 2 8 d a y s pri or t o s cr e e ni n g vi sit; or
 Stri ct a b sti n e n c e (i. e., r efr ai ni n g fr o m h et er o s e x u al i nt er c o ur s e f or 
t h e e ntir e d ur ati o n of t h e s u bj e ct' s p arti ci p ati o n i n t h e st u d y ).
7. Ti m e a n d a bilit y t o c o m pl et e t h e st u d y a n d c o m pl y wit h i n str u cti o n s.
8. U n d er st a n d s t h e st u d y r e q uir e m e nt s a n d si g n e d t h e i nf or m e d c o n s e nt 
f or m (I C F).Title  D o c i d  
[ADDRESS_1103387] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103388] u d y  Titl e: A M ulti c e nt er, R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o -C o ntr oll e d St u d y t o E v al u at e t h e Effi c a c y 
a n d S af et y of Q M 1 1 1 4 -D P f or t h e Tr e at m e nt of M o d er at e t o S e v er e L at er al C a nt h al Li n e s ( L C L) a n d Gl a b ell ar Li n e s 
( G L) Al o n e or i n C o m bi n ati o n ( R E A D Y – 3)
K e y E x cl u si o n Crit eri a: 1. Pr e vi o u s u s e of a n y B ot uli n u m t o xi n i n f a ci al ar e a s wit hi n [ADDRESS_1103389] u d y ( ot h er t h a n t h e i n v e sti g ati o n al 
pr o d u ct).
3. F e m al e w h o i s pr e g n a nt, br e a st f e e di n g, or i nt e n d s t o c o n c ei v e a 
c hil d d uri n g t h e st u d y.
4. K n o w n all er g y or h y p er s e n siti vit y t o a n y c o m p o n e nt of t h e 
i n v e sti g ati o n al pr o d u ct ( Q M 1 1 1 4-D P) .
5. I n a bilit y t o s u b st a nti all y re d u c e t h e a p p e ar a n c e of f a ci al r h yti d e s i n 
t h e tr e at m e nt ar e a b y p h y si c all y s pr e a di n g t h e m a p art, a s 
d et er mi n e d b y t h e I n v e sti g at or.
6. Cli ni c all y si g nifi c a nt a b n or m al f o c u s e d p h y si c al e x a mi n ati o n 
fi n di n g( s) at s cr e e ni n g or b a s eli n e vi sit s , i n t h e i n v e sti g at or’ s 
o pi [INVESTIGATOR_9384] o n .
7. E x c e s si v e s ki n l a xit y i n t h e tr e at m e nt ar e a or p eri or bit al ar e a .
8. Pr e vi o u s u s e of a n y h y al ur o ni c a ci d s oft ti s s u e a u g m e nt ati o n 
t h er a p y i n t h e l at er al c a nt h al or gl a b ell a ar e a wit hi n 6 m o nt h s b ef or e 
b a s eli n e .
9. Pr e vi o u s s oft ti s s u e a u g m e nt ati o n wit h a n y p er m a n e nt ( n o n-
bi o d e gr a d a bl e s u c h a s sili c o n e, p ol y a cr yl a mi d e, et c .) or s e mi -
p er m a n e nt (e. g ., c al ci u m h y dr o x yl a p atit e, P ol y - L-L a cti c a ci d or 
p ol y m et h yl -m et h a cr yl at e) pr o d u ct ; lifti n g t hr e a d s, or a ut ol o g o u s f at 
i n t h e tr e at m e nt ar e a. 
[ADDRESS_1103390] or y, pr e s e n c e, or pr e di s p o siti o n of e y eli d or e y e br o w pt o si s 
( h e a v y e y e br o w s), a m bl y o pi a (i. e., l a z y e y e), or pr e vi o u s s ur g er y 
ar o u n d t h e e y e t h at m a y l e a d t o t h e a b o v e e v e nt s, a s d et er mi n e d 
b y t h e I n v e sti g at or.
1 1. M ar k e d f a ci al a s y m m etr y, e x c e s si v e d er m at o c h al a si s (i. e., e x c e s s 
of s ki n i n e y eli d s), or m ar k e d p eri o c ul ar or e y e br o w a s y m m etr y.
1 2. Pr e s e n c e of s c ar( s) , pi [INVESTIGATOR_799851] n g( s), or t att o o s (i n cl u di n g mi cr o bl a di n g 
of e y e br o w or e y eli n er) i n t h e tr e at m e nt ar e a or ar o u n d t h e 
tr e at m e nt ar e a, t h at i n t h e I n v e sti g at or' s o pi [INVESTIGATOR_9384] o n, m a y i nt erf er e wit h 
st u d y e v al u ati o n s .
[ADDRESS_1103391] h eti c 
pr o c e d ur e s ( e. g. a bl ati v e s ki n r e s urf a ci n g, l a s er tr e at m e nt,
mi cr o n e e dli n g, or c h e mi c al p e el ) i n t h e pr e vi o u s 1 2 m o nt h s t h at, i n 
t h e I n v e sti g at or’ s o pi [INVESTIGATOR_9384] o n , c o ul d i nt erf er e wit h st u d y inj e cti o n s 
a n d/ or a s s e s s m e nt s or e x p o s e t h e s u bj e ct t o u n d u e ri s k b y st u d y 
p arti ci p ati o n.
[ADDRESS_1103392] a n n e d f a ci al s ur g er y, e y e s ur g er y (i n cl u di n g L A SI K pr o c e d ur e) or 
a e st h eti c pr o c e d ur e s ( e. g. a bl ati v e s ki n r e s urf a ci n g, l a s er Title  D o c i d  
[ADDRESS_1103393] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103394] u d y  Titl e: A M ulti c e nt er, R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o -C o ntr oll e d St u d y t o E v al u at e t h e Effi c a c y 
a n d S af et y of Q M 1 1 1 4 -D P f or t h e Tr e at m e nt of M o d er at e t o S e v er e L at er al C a nt h al Li n e s ( L C L) a n d Gl a b ell ar Li n e s 
( G L) Al o n e or i n C o m bi n ati o n ( R E A D Y – 3)
tr e at m e nt, mi cr o n e e dli n g, or c h e mi c al p e el i n t h e u p p er or mi df a ci al 
ar e a) d uri n g t h e st u d y p eri o d .
[ADDRESS_1103395] h a s a n y pri or or c urr e nt p s y c hi atri c ill n e s s ( e. g. p s y c h o s i s, 
d e pr e s si o n, a n xi et y), al c o h ol or dr u g a b u s e, or i s t a ki n g 
a nti d e pr e s s a nt, a n xi ol yti c, or a nti p s y c h oti c m e di c ati o n t h at, i n t h e 
I n v e sti g at or' s o pi [INVESTIGATOR_9384] o n, c o ul d aff e ct t h e s u bj e ct' s s af et y a n d/ or t h e 
c o n d u ct or o ut c o m e of t h e st u d y.
2 1. Ot h er c o n c urr e nt m e di c al c o n diti o n s, t h er a p y or ot h er c o n diti o n t h at 
i n t h e I n v e sti g at or' s o pi [INVESTIGATOR_9384] o n w o ul d i nt erf er e wit h t h e e v al u ati o n of 
t h e st u d y m e di c ati o n s af et y or effi c a c y a n d/ or p ut t h e s u bj e ct at ri s k 
if h e/ s h e p arti ci p at e s t o t h e st u d y.
[ADDRESS_1103396] u d y c e nt er 
p er s o n n el ( e. g. p ar e nt s, c hil dr e n, si bli n g s, or s p o u s e), e m pl o y e e s 
or cl o s e r el ati v e s of e m pl o y e e s at t h e S p o n s or c o m p a n y .
I n v e sti g ati o n al Pr o d u ct: Q M 1 1 1 4 -D P , b uff er e d s ol uti o n f or i nj e cti o n
Str e n gt h/ C o n c e ntr ati o n: 1 0 0 U/ m L
D o s a g e (t ot al d o s e): T h e m a xi m u m t ot al d o s e i s 1 1 0 U ( 1. 1 0 m L) of Q M [ADDRESS_1103397] er e d 
a s:
 6 0 U t ot al ( 0. 6 m L t ot al/ 0. 3 m L p er tr e at m e nt si d e)
1 0 U p er L C L i nj e cti o n p oi nt ( 0. 1 m L p er L C L i nj e cti o n p oi nt)
A N D/ O R
 5 0 U t ot al ( 0. 5 m L t ot al)
1 0 U p er G L i nj e cti o n p oi nt ( 0. 1 m L p er G L i nj e cti o n p oi nt)
R o ut e: I ntr a m u s c ul ar i nj e cti o n
D o s e r e gi m e n: Si n gl e tr e at m e nt at b a s eli n e vi sit
L o c ati o n of tr e at e d ar e a: L at er al c a nt h u s a n d gl a b ell ar ar e a s
Pl a c e b o Pr o d u ct: Pl a c e b o , b uff er e d s ol uti o n f or i nj e cti o n
Str e n gt h/ C o n c e ntr ati o n: N/ A
D o s a g e (t ot al d o s e): T h e m a xi m u m t ot al d o s e i s 1. [ADDRESS_1103398] er e d a s:
 0. 6 m L t ot al ( 0. 3 m L p er tr e at m e nt si d e)
0. 1 m L p er L C L i nj e cti o n p oi nt
A N D/ O R
 0. 5 m L t ot al
0. 1 m L p er G L i nj e cti o n p oi nt
R o ut e: I ntr a m u s c ul ar i nj e cti o n
D o s e r e gi m e n: Si n gl e tr e at m e nt at b a s eli n e vi sitTitle  D o c i d  
[ADDRESS_1103399] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103400] u d y  Titl e: A M ulti c e nt er, R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o -C o ntr oll e d St u d y t o E v al u at e t h e Effi c a c y 
a n d S af et y of Q M 1 1 1 4 -D P f or t h e Tr e at m e nt of M o d er at e t o S e v er e L at er al C a nt h al Li n e s ( L C L) a n d Gl a b ell ar Li n e s 
( G L) Al o n e or i n C o m bi n ati o n ( R E A D Y – 3)
L o c ati o n of tr e at e d ar e a: L at er al c a nt h u s a n d gl a b ell ar ar e a s
Effi c a c y  A s s e s s m e nt s :
 I n v e sti g at or 4- p oi nt P h ot o gr a p hi c S c al e of L C L S e v erit y at  
 m a xi m u m s mil e (I n v e sti g at or a s s e s s m e nt [ L C L-I L A])
 S u bj e ct 4- p oi nt P h ot o gr a p hi c S c al e of L C L S e v erit y at  
 m a xi m u m s mil e ( s u bj e ct a s s e s s m e nt [ LC L -S L A] )
 I n v e sti g at or 4- p oi nt P h ot o gr a p hi c S c al e of G L S e v erit y at  
m a xi m u m fr o w n (I n v e sti g at or a s s e s s m e nt [ G L -I L A])
 S u bj e ct St ati c 4- p oi nt C at e g ori c al S c al e of G L S e v erit y at m a xi m u m 
fr o w n ( s u bj e ct a s s e s s m e nt [ G L-S L A])
St u d y  O bj e cti v e: T h e o bj e cti v e of t h e st u d y i s t o e v al u at e t h e effi c a c y a n d s af et y of a si n gl e 
d o s e of Q M 1 1 1 4 - D P f or t h e tr e at m e nt of m o d er at e t o s e v er e L C L a n d G L, 
al o n e or i n c o m bi n ati o n .
Pri m ar y  Effi c a cy O bj e cti v e a n d 
E n d p oi nt:T h e pri m ar y o bj e cti v e of t hi s st u d y i s t o e v al u at e t h e effi c a c y of a si n gl e d o s e 
of [ADDRESS_1103401] w h o a c hi e v e s gr a d e/l e v el [ADDRESS_1103402] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103403] u d y  Titl e: A M ulti c e nt er, R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o -C o ntr oll e d St u d y t o E v al u at e t h e Effi c a c y 
a n d S af et y of Q M 1 1 1 4 -D P f or t h e Tr e at m e nt of M o d er at e t o S e v er e L at er al C a nt h al Li n e s ( L C L) a n d Gl a b ell ar Li n e s 
( G L) Al o n e or i n C o m bi n ati o n ( R E A D Y – 3)
S e c o n d ar y  Effi c a cy O bj e cti v e s a n d 
E n d p oi nt s:T o e v al u at e t h e effi c a c y of a si n gl e d o s e of [ADDRESS_1103404] a c e b o f or 
t h e tr e at m e nt of m o d er at e t o s e v er e L C L a n d G L.
E n d p oi nt s : 
P er c e nt a g e of s u bj e ct s w h o a c hi e v e gr a d e 0 or 1 at:
 E a c h p o st -tr e at m e nt vi sit ( e x cl u di n g M o nt h 1) u si n g t h e G L -I L A at 
m a xi m u m fr o w n
 E a c h p o st -tr e at m e nt vi sit ( e x cl u di n g M o nt h 1) u si n g t h e L C L -I L A at 
m a xi m u m s mil eTitle  D o c i d  
[ADDRESS_1103405] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103406] u d y  Titl e: A M ulti c e nt er, R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o -C o ntr oll e d St u d y t o E v al u at e t h e Effi c a c y 
a n d S af et y of Q M 1 1 1 4 -D P f or t h e Tr e at m e nt of M o d er at e t o S e v er e L at er al C a nt h al Li n e s ( L C L) a n d Gl a b ell ar Li n e s 
( G L) Al o n e or i n C o m bi n ati o n ( R E A D Y – 3)
S af et y  A s s e s s m e nt s :A d v er s e e v e nt s ( A E s)
F o c u s e d p h y si c al e x a mi n ati o n ( F P E)
Vit al si g n s
El e ctr o c ar di o gr a m ( E C G)
L a b or at or y s af et y t e st s ( c h e mi str y a n d h e m at ol o g y)
Pr o d u cti o n of n e utr ali zi n g a nti b o di e s a g ai n st Q M 1 1 1 4 -D P
S af et y  O bj e cti v e s a n d E n d p oi nt s: T o e v al u at e t h e s af et y of a si n gl e d o s e of [ADDRESS_1103407] a c e b o f or t h e tr e at m e nt of m o d er at e t o s e v er e L C L a n d G L.
E n d p oi nt s:
I n ci d e n c e a n d s e v erit y of tr e at m e nt e m er g e nt A E s ( T E A E s)
F P E fi n di n g s 
Vit al si g n s
E C G
L a b or at or y p ar a m et er s ( cli ni c al c h e mi str y a n d h e m at ol o g y)
N e utr ali zi n g a nti b o d y pr o d u cti o nTitle  D o c i d  
[ADDRESS_1103408] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103409] u d y  Titl e: A M ulti c e nt er, R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o -C o ntr oll e d St u d y t o E v al u at e t h e Effi c a c y 
a n d S af et y of Q M 1 1 1 4 -D P f or t h e Tr e at m e nt of M o d er at e t o S e v er e L at er al C a nt h al Li n e s ( L C L) a n d Gl a b ell ar Li n e s 
( G L) Al o n e or i n C o m bi n ati o n ( R E A D Y – 3)
Ot h er A s s e s s m e nt s:  P h ot o gr a p h y
 Pr e g n a n c y t e st
Bli n di n g: T hi s i s a d o u bl e -bli n d st u d y i n w hi c h n eit h er t h e I n v e sti g at or, s u b -
I n v e sti g at or, st u d y st aff, n or t h e s u bj e ct will k n o w t h e s u bj e ct' s st u d y pr o d u ct 
a s si g n m e nt (i. e., Q M 1 1 1 4 -D P a n d/ or pl a c e b o). Pl a c e b o i s i d e nti c al i n 
a p p e ar a n c e t o Q M [ADDRESS_1103410] ati sti c al M et h o d: T h e pri m ar y effi c a c y e n d p oi nt s will b e a c o m p o sit e r e s p o n d er r at e at 
M o nt h [ADDRESS_1103411] w h o a c hi e v e s gr a d e/l e v el [ADDRESS_1103412] ( str atifi e d b y c e nt er) at 5 % si g nifi c a n c e l e v el 
( 2-si d e d). T h e gr o u p tr e at e d i n o n e r h yti d ar e a ( L C L or G L) al o n e , a n d t h e 
gr o u p wit h c o n c urr e nt L C L a n d G L tr e at m e nt will b e a n al y z e d s e p ar a t el y. T o 
c o ntr ol t h e t y p e I err or r at e a m o n g t h e [ADDRESS_1103413] m e nt t o t h e 
l e v el of si g nifi c a n c e. T h e c o m p ari s o n s will b e d o n e i n t h e f oll o wi n g or d er:
1. G L al o n e gr o u p v s pl a c e b o o n t h e G L s c al e
2. G L + L C L gr o u p v s pl a c e b o o n t h e G L s c al e
3. L C L al o n e gr o u p v s pl a c e b o o n t h e L C L s c al e
4. G L + L C L gr o u p v s pl a c e b o o n t h e L C L s c al e
All ot h er e n d p oi nt s will b e a n al y z e d d e s cri pti v el y. F or effi c a c y, p er c e nt a g e s 
of s u bj e ct s o v er ti m e will b e pr e s e nt e d i n gr a p h s. D ur ati o n of tr e at m e nt eff e ct 
a n d ti m e t o o n s et will b e a n al y z e d wit h K a pl a n -M ei er m et h o d s.
S a m pl e Si z e: T h e st u d y w a s i niti all y pl a n n e d t o e nr oll a p pr o xi m at el y [ADDRESS_1103414] s w h o will 
b e tr e at e d wit h eit h er: 
 6 0 u nit s Q M 1 1 1 4 -D P 
( [ADDRESS_1103415] s),
 5 0 u nit s Q M 1 1 1 4 -D P 
( [ADDRESS_1103416] s),
 1 1 0 u nit s Q M 1 1 1 4 -D P 
( [ADDRESS_1103417] s), or 
 Pl a c e b o i n b ot h t h e L C L a n d G L ( [ADDRESS_1103418] s).
T h e s a m pl e si z e i s d et er mi n e d b y t h e n u m b er of s u bj e ct s e x p o s e d t o 
Q M [ADDRESS_1103419] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103420] u d y  Titl e: A M ulti c e nt er, R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o -C o ntr oll e d St u d y t o E v al u at e t h e Effi c a c y 
a n d S af et y of Q M 1 1 1 4 -D P f or t h e Tr e at m e nt of M o d er at e t o S e v er e L at er al C a nt h al Li n e s ( L C L) a n d Gl a b ell ar Li n e s 
( G L) Al o n e or i n C o m bi n ati o n ( R E A D Y – 3)
T h e st u d y i s pl a n n e d t o e nr oll a p pr o xi m at el y [ADDRESS_1103421] s w h o will b e tr e at e d 
wit h eit h er:
 6 0 u nit s Q M 1 1 1 4 -D P 
( [ADDRESS_1103422] s),
 5 0 u nit s Q M 1 1 1 4 -D P 
( [ADDRESS_1103423] s),
 1 1 0 u nit s Q M 1 1 1 4 -D P 
( [ADDRESS_1103424] s), or 
 Pl a c e b o i n b ot h t h e L C L a n d G L ( [ADDRESS_1103425] s).
I nt eri m A n al ysi s (I A): N ot a p pli c a bl e.  A n i nt eri m a n al y si s i s n ot pl a n n e d f or t hi s st u d y. Title  D o c i d  
[ADDRESS_1103426] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103427] u d y Sc he m atic
                                  S cr e e ni n g
                                 
                                     B a s eli n e/ R a n d o mi z ati o n t o Tr e at m e nt
                                  
Gr o u p 1 Gr o u p 2 Gr o u p 3 Gr o u p 4
n = 1 1 8 n = 1 1 8 n = 1 1 8 n = [ADDRESS_1103428] a c e b o i n G L
Tr e at m e nt 
Fr e q u e n c yTr e at m e nt at b a s eli n e Tr e at m e nt at b a s eli n e Tr e at m e nt at b a s eli n e Tr e at m e nt at b a s eli n e
                                  
                                F oll o w u p Vi sit s
                                        D a y s 7 a n d 1 4, a n d M o nt h s 1, 2, 3, 4, 5, a n d 6/ E TTitle  D o c i d  
[ADDRESS_1103429] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103430] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C CI
C O N FI D E N TI A L
Pa ge 2 0 of 9 6S C H E D U L E O F A S S E S S M E N T S
T a ble 2 Sc he d ule of A ssess me nts
Defi niti o n 1 m o nt h = 4 wee ks / 2 8 da ys
All visit wi n d o ws are calc ulate d fr o m Baseli ne/ Da y 0Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 1 0
Scree ni n g1Baseli ne/ Da y 01
( wit hi n 2 wee ks after 
scree ni n g)Da y 7
( ±1 da y )Da y 1 4
( 3 da ys)M o nt h 1
( 5 da y s)M o nt h 2
( 5 da y s)M o nt h 3
( 5 da y s)M o nt h 4
( 5 da y s)M o nt h 5
( 5 da y s)M o nt h 6/ E T2
( 5 da y s)
I nf or me d C o nse nt X
De m o gra p hic Data3i ncl u di n g, Fitz patric k s ki n t y pe, me dical 
hist or y & c o nc urre nt diseases, pre vi o us facial 
treat me nts/ pr oce d ures (t o xi n naï ve/ n o n-t o xi n naï ve)X
I ncl usi o n / E xcl usi o n Criteria X X4
C o nc o mita nt T hera pi[INVESTIGATOR_014] / Pr oce d ures X X X X X X X X X X
A d verse E ve nts X X5X X X X X X X X
Uri ne Pre g na nc y Test6X X4X
Vital Si g ns ( bl o o d press ure, heart rate, a n d res pi[INVESTIGATOR_1305] y rate)7X5X X X X
E C G X 4X X
Bl o o d sa m ple cli nical c he mistr y a n d he mat ol o g y X 4X
Bl o o d sa m ple f or ser u m a nti b o d y testi n g X 4X X
La teral Ca nt hal Li nes Se verit y ( L C L-I L A) X X4X X X X X X X X
Gla bellar Li ne Se verit y ( G L -I L A) X X4X X X X X X X X
F oc use d P h ysical E xa mi nati o n (face, hea d, nec k)8X X4X X X X
P h ot o gra p h y X4X X X X X X X X
Ra n d o mizati o n X4
Treat me nt X9
S u bject assess me nts
La teral Ca nt hal Li nes Se verit y ( L C L-S L A)1 0X X4X X X X X X X X
Gla bellar Li ne Se verit y ( G L -S L A)[ADDRESS_1103431] u dy assess me nts o nce 
(i.e., P E, U P T, S L A, I L A, A E, c o nc o mit a nt t her a pi[INVESTIGATOR_014]/ pr oce d ures , i ncl usi o n/excl usi o n revie w)
2. If t he s u bject wit h dr a ws bef ore t he fi n al visit t he assess me nts at M o nt h 6/ E T s h o ul d be c o m plete d, if p ossi ble.
3. I ncl u des d ate of birt h, ge n der, r ace, et h nicity, hei g ht, a n d wei g ht.
4. T o be perf or me d bef ore tre at me nt.
5. T o be perf or me d bef ore tre at me nt a n d p ost -tre at me nt.
6. Fe m ales of c hil d be ari n g p ote nti a l.
7.Vit al si g ns are t ake n se ate d after [ADDRESS_1103432] a w  (excl u di n g p ost -tre at me nt 
me as ure me nts o n D ay 0).8.P ost- b aseli ne, eve nts s u g gestive of re m ote s pre a d of t oxi n are als o c o nsi dere d w hile d oi n g cli nic al ev al uati o ns b ase d 
o n t he s u bject’s sy m pt o ms a n d si g ns. Directe d q uesti o ni n g a n d ex a mi n ati o n will t he n be perf or me d as a p pr o pri ate.
9.F oll o wi n g tre at me nt a d mi nistr ati o n, s u bjects will be m o nit ore d at t he st u dy ce nter f or 3 0 mi n utes.
1 0.S u bjects will m ake t heir L ater a l C a nt h al Li ne a n d/ or Gl a bell ar Li ne assess me nts i n de pe n de ntly of t he I nvesti g at or’s 
assess me nt.Title  D o c i d  
[ADDRESS_1103433] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1
Versi o n : Effecti ve  date: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C CI
C CI
C O N FI D E N TI A L
Pa ge 2 1 of 9 6LI S T O F A B B R E VI A TI O N S A N D D E FI NI TI O N S O F T E R M S
A b brevi ati o n / Ter m Defi niti o n
C De grees Celsi us
A E A d verse E ve nt
A L P Al kali ne P h os p hatase
A L T/ A L A T ( S G P T) Ala ni ne A mi n otra nsferase ( Ser u m Gl uta mic P yr u vic Tra nsa mi nase)
A S T/ A S A T ( S G O T) As partate A mi n otra nsferase ( Ser u m Gl uta mic O xal oacetic 
Tra nsa mi nase)
B o N T B ot uli n u m T o xi n
B o N T - A B ot uli n u m T o xi n T y pe A
C F R C o de of Fe deral Re g u lati o ns
C R O C o ntract Researc h Or ga nizati o n
C S P Cli nical St u d y  Pr ot oc ol
C S R Cli nical St u d y  Re p ort
C T A Cli nical Trial A gree me nt
C T N Cli nical Trial N u m ber
D M P Data Ma na ge me nt Pla n
E C G Electr ocar di o gra m
e C R F Electr o nic Case Re p ort F or m
E D C Electr o nic Data Ca pt ure
e. g. F or E xa m ple ( Lati n: e xe m pli gratia)
E T Earl y Ter mi nati o n
F De grees Fa hre n heit
F D A F o o d a n d Dr u g A d mi nistrati o n
F S F V First S u bject First Visit (first s u bject scree ne d, i.e. w h o si g ns t he 
i nf or me d c o nse nt f or m)
F S L V First S u bject L ast Visit
G C P G o o d Cli nical Practice 
G G T Ga m ma Gl uta m yl  Tra nsferase
G L Gla bellar Li nesTitle  D o c i d  
[ADDRESS_1103434] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C CI
C CI
C O N FI D E N TI A L
Pa ge 2 2 of 9 6A b brevi ati o n / Ter m Defi niti o n
G L P G o o d La b orat or y  Practices
H b Hae m o gl o bi n
Hct He mat ocrit
HI P A A Healt h I ns ura nce P orta bilit y  a n d Acc o u nta bilit y Act of 1 9 9 6
I B I n vesti gat or’s Br oc h ure
I CF I nf or me d C o nse nt F or m
I C H I nter nati o nal C o u ncil f or Har m o nisati o n 
i.e. T hat is ( Lati n: i d est)
I L A I n vesti gat or Li ve Assess me nt
I M I ntra m usc ular
I ND I n vesti gati o nal Ne w Dr u g
I n vesti gat or T he Pri nci pal I nvesti gat or ( PI) or ot her q ualifie d pers o n, i.e. s u b-
In vesti gat or, desi g nate d a n d s u per vise d b y  the PI  [INVESTIGATOR_136] a st u d y site t o 
perf or m critical st u d y -relate d pr oce d ures or t o ma ke i m p orta nt st u d y-
relate d decisi o ns as s pecifie d o n t he si g nat ure a n d dele gati o n l o g
I n vesti gat or File Esse ntial d oc u me nts relati n g t o a cli nical st u d y as defi ne d i n 
a p plica ble G C P g ui da nce d oc u me nt a n d mai ntai ne d b y  the 
In vesti gat or.
I n vesti gati o nal Pr o d uct A p har mace utical f or m of a n acti ve i n gre die nt bei n g teste d i n a cli nical 
st u d y, i ncl u di n g a pr o d uct wit h a mar keti n g aut h orizati o n w he n use d 
or asse m ble d (f or m ulate d or pac ka ge d) i n a wa y differe nt fr o m t he 
a p pr o ve d f or m, or w he n use d f or a n u na p pr o ve d i n dicati o n, or w he n 
use d t o gai n f urt her i nf or mati o n a b o ut a n a p pr o ve d use.
I RB I nstit uti o nal Re vie w B oar d
I T T I nte nti o n-t o-treat
I UD I ntra uteri ne De vice
k Da K il o dalt o n
K M Ka pla n -Meier
L C L Lateral Ca nt hal Li nes
L S F V Last S u bject First Visit (last s u bject scree ne d, i.e. w h o si g ns t he 
i nf or me d c o nse nt f or m)
L S L V Last S u bject Last Visit (last s u bject w h o c o m plete d its last cli nical 
st u d y visit)
M A S Merz Aest hetic s ScaleT M
M D Me dical D oct orTitle  D o c i d  
[ADDRESS_1103435] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 2 3 of 9 6A b brevi ati o n / Ter m Defi niti o n
Me d D R A Me dical Dicti o nar y  f or Re g ulat or y Acti vities
m g Milli gra m
mI T T M o difie d I nte nti o n-t o-treat
m L Milliliter
M T D Ma xi m u m t olerate d d ose
N or n N u m ber
N/ A N ot A p plica ble
N A B Ne utralizi n g A nti b o d y
O T C O ver -t he-C o u nter
P E P h y sical E xa mi nati o n
PI [INVESTIGATOR_1307] I n vesti gat or; q ualifie d pers o n res p o nsi ble f or c o n d ucti n g t he 
st u d y at a st u d y site
Plt Platelet c o u nt
P P Per- Pr ot oc ol
P Q C Pr o d uct Q ualit y  C o m plai nt
P T Preferre d Ter m
Q A Q ualit y  Ass ura nce
R A Re g ulat or y  A ut h orit y
R B C Re d bl o o d cell
Refere nce pr o d uct A n i n vesti gati o nal or mar kete d pr o d uct (i.e. acti ve c o ntr ol), or 
place b o, use d as a c o m parat or i n a cli nical st u d y
S A E Seri o us A d verse E ve nt
S A P Statistical A nal y sis Pla n
S O C S y ste m Or ga n Class
S O P Sta n dar d O perati n g Pr oce d ure
S p o ns or File Esse ntial d oc u me nts relati n g t o a cli nical st u d y as defi ne d i n 
a p plica ble G C P g ui da nce d oc u me nt a n d mai ntai ne d b y  t he S p o ns or.
S L A S u bject Li ve Assess me nt
St u d y  Files T he In vesti gat or file a n d t he S p o ns or file
St u d y  Pr o d ucts T he i n vesti gati o nal pr o d uct a n d t he refere nce pr o d uct u n der st u d y
St u d y  Site T he l ocati o n(s) w here t he st u d y-relate d acti vities are act uall y 
c o n d ucte d
T E A E Treat me nt E mer ge nt A d verse E ve ntTitle  D o c i d  
[ADDRESS_1103436] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 2 4 of 9 6A b brevi ati o n / Ter m Defi niti o n
U P T Uri ne Pre g na nc y  Test
U S U nite d States
v/ v V ol u me/ v ol u me
W B C W hite bl o o d cell
W FI Water f or i njecti o n
W H O W orl d Healt h Or ga nizati o nTitle  D o c i d  
[ADDRESS_1103437] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103438] u d y
B ot uli n u m t o xi n ( B o N T) is a p ote nt ne ur ot o xic pr otei n pr o d uce d b y  t he Gra m-p ositi ve a naer o bic 
bacteri u m, Cl ostri di u m b ot uli n u m . T he m olec ule is pr o d uce d nat urall y b y  these bacteria t o get her 
wit h a series of access or y pr otei ns, f or mi n g w hat is ter me d t he “t o xi n c o m ple x”. T he ne ur ot o xi n is 
t he ca use of t he se vere a n d p ote ntiall y fatal disease of b ot ulis m. In a d diti o n, t he pr otei n is use d i n 
ver y  s mall q ua ntities as a treat me nt m o dalit y f or aest hetic a n d me dical i n dicati o ns, ma n y of w hic h 
are c haracterize d b y  i ncrease d m uscle acti vit y. B ot uli n u m t o xi ns occ ur i n se ve n k n o w n ser ot y pes 
( A-G) t hat are pr o d uce d b y  differe nt strai ns of Cl ostri di u m b ot uli n u m . Cli nicall y -i m p orta nt 
bi ol o gic acti vit y is li mite d pri maril y t o t he A a n d B ser oty pes, of w hic h t he t yp e A ser oty pe ( B o N T-
A) is use d wi del y t hr o u g h o ut t he w orl d f or t he treat me nt of a ra n ge of cli nical c o n diti o ns.
B o N T -A bl oc ks t he release of acet yl c h oli ne i nt o t he ne ur o m usc ular j u ncti o n (s yna p se) cleft, 
t here by [INVESTIGATOR_21032] o hi biti n g t he acti vati o n of acet yl c h oli ne rece pt ors. Paresis b y c he mical de ner vati o n t h us 
occ urs i n t he tar get m uscle, lea di n g t o i n hi biti o n of m usc ular c o ntracti o n. T he acti ve ne ur ot o xi n is 
1 5 0 k Da m olec ular wei g ht a n d Q M 1 1 1 4 -D P o nl y  c o ntai ns t his part of t he t o xi n c o m ple x: t here are 
n o ne of t he ot her access or y pr otei ns w hic h are n or mall y  ass ociate d wit h t he [ADDRESS_1103439] hetic i n dicati o ns of gla bellar li nes ( G L), lateral ca nt hal 
li nes ( LC L ) a n d f ore hea d li nes ( F L), t o get her wit h t hera pe utic i n dicati o ns s uc h as stra bis m us, 
ble p har os pas m, he mifacial s pas m, cer vical d y st o nia, f ocal s pasticity, pr o p h y lactic treat me nt of 
c hr o nic mi grai ne, o veracti ve bla d der a n d h y p er hi dr osis. 
I n t he earl y [ADDRESS_1103440]-treat me nt.1 0
T here are f o ur B o N T -A pr o d ucts c urre ntl y lice nse d i n t he Unite d States ( U S) f or t he treat me nt of 
G L ( B ot o x C os metic®, D ys p ort®, Xe o mi n® , a n d Je u vea uT M), a n d o ne lice nse d f or t he treat me nt of 
L C L ( B ot o x C os metic®). Q M [ADDRESS_1103441] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103442] u g P r ofile
Q M 1 1 1 4 is a pr otei n di mer of 1 5 0 kil o dalt o n ( k Da)  
 
 
 U nli ke ot her c o m mercially 
a vaila ble B o N Ts, Q M [ADDRESS_1103443] u dies t o 
s u p p ort safety f or a d mi nistrati o n of Q M 1 1 1 4 -D P at t he pr o p ose d d ose of 5 0 u nit ( U), [ADDRESS_1103444] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103445] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103446] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103447] u d y of Q M 1 1 1 4 -D P usi n g t hree differe nt si n gle d oses of 
Q M 1 1 1 4 -D P ( 3 0, 4 5, 6 0 U ) i n male or fe male s u bjects a ge d o ver [ADDRESS_1103448] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103449] u dies ha ve s h o w n a si milarit y bet wee n Q M 1 1 1 4 -D P p ote nc y  units a n d S pe y w o o d 
u nits (i.e., t he D y s p ort®/ Azzal ure®pr o d uct ). I n t he treat me nt of t he L C L wit h S pe y w o o d u nits t he 
rec o m me n de d d ose is [ADDRESS_1103450] u d y ( ). F or treat me nt i n t he L C L t he 
6 0 U d ose has bee n selecte d f or f urt her cli nical de vel o p me nt , a n d for treat me nt i n t he G L t he 5 0 U 
d ose has bee n selecte d.  For t he c o m bi ne d L C L a n d G L treat me nt, Q M 1 1 1 4 -D P was e val uate d at 
t w o asce n di n g d ose le vels (i.e., 1 1 0 U [ 5 0 U i n t he G L a n d 6 0 U i n t he L C L] , an d 1 4 0 U [ 5 0 U i n 
t he G L a n d 9 0 U i n t he L C L). T he 1 1 0 U d ose has bee n selecte d f or f urt her cli nical de vel o p me nt i n 
t he treat me nt of L C L a n d G L . T his is c o nsiste nt wit h t he c o m bi ne d rec o m me n de d S p e y w o o d u nit 
d oses i n eac h treat me nt area as well as cli nical e x perie nce, as s pecifie d a b o ve.
1. 3 Ris k/ Be nefit A ssess me nt
I n t he p hase 2 st u d y ( C T N 4 3 Q M 1 3 1 3; G L treat me nt area o nly ), Q M [ADDRESS_1103451] u d y will be a te m p orar y re d ucti o n i n t he 
ap peara nce of t heir L C L a n d/ or G L.  T he s u bjects i n t he place b o gr o u p are n ot e x pecte d t o gai n a n y 
cli nical be nefit fr o m t heir partici pati o n i n t he st u d y; h o we ver, as t his is a n aest hetic i n dicati o n t here 
are n o se q uelae t o lac k of efficac y be yo n d a disa p p o i nt me nt i n t he re d ucti o n of se verit y of t heir L C L
a n d/ or G L . I n a d diti o n, o nl y  o ne s u bject o ut of se ve n will recei ve place b o o nl y  i n t he st u d y; m ost 
s u bjects ( 6/ 7 s u bjects) will recei ve Q M 1 1 1 4 -D P i n o ne or b ot h treat me nt areas (i.e., L C L a n d/ or 
G L).Title  D o c i d  
[ADDRESS_1103452] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103453].
I n c o ncl usi o n, gi ve n t he a ntici pate d l o w le vel of tra nsie nt a n d acce pta ble ris ks, t he ris k/ be nefit 
assess me nt of t he use of Q M [ADDRESS_1103454] w h o 
ac hie ves gra de/le vel [ADDRESS_1103455] w h o 
ac hie ves gra de/le vel [ADDRESS_1103456] u d y  are:
O bjecti ve: T o e val uate t he efficac y of a si n gle d ose of [ADDRESS_1103457] b o f or t he treat me nt of m o derate 
t o se vere L C L a n d G L.
E n d p oi nt: Perce n ta ge of s u bjects w h o ac hie ve a sc ore or 0 or 1 at:Title  D o c i d  
[ADDRESS_1103458] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 3 2 of 9 6Eac h p ost -treat me nt visit (e xcl u di n g m o nt h 1) usi n g t he G L-I L A at ma xi m u m fr o w n
Eac h p ost -treat me nt visit (e xcl u di n g m o nt h 1) usi n g t he L C L-I L A at ma xi m u m s mileTitle  D o c i d  
[ADDRESS_1103459] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103460] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103461] b o f or t he treat me nt of m o derate 
t o se vere L C L a n d G L.
Saf et y e n d p oi nts i ncl u de:
I nci de nce a n d se verit y of T E A Es
F oc use d p h ys ical e xa mi nati o n ( FP E ) fi n di n gs 
Vital si g ns
Electr ocar di o gra m ( E C G)
La b orat or y  para meters (cli nical c he mistr y a n d he mat ol o g y)
Ne utralizi n g a nti b o d y pr o d ucti o n
2. [ADDRESS_1103462] u d y 
wit h treat me nt of Q M 1 1 1 4- D P i n t he L C L  a n d G L, al o ne or i n c o m bi nati o n.
F oll o wi n g t he i nf or me d c o nse nt a n d t he scree ni n g pr ocess, eli gi ble s u bjects will be ra n d o mly 
assi g ne d t o treat me nt i n a 2: 2: 2: 1 rati o. S u bjects will recei ve a si n gle treat me nt at baseli ne ( Da y 0) 
of eit her:
6 0 u nits Q M 1 1 1 4 -D P ( [ADDRESS_1103463] b o i n t he G L, 11 8 s u bjects),
5 0 u nits Q M 1 1 1 4 -D P ( [ADDRESS_1103464] b o i n t he L C L, 1 1 8 s u bjects),
1 1 0 u nits Q M 1 1 1 4 -D P ( 6 0 u nits i n t he L C L  a n d 5 0 u nits i n t he G L, 1 1 8 s u bjects), or
P lace b o i n b ot h t he LC L  a n d G L ( 59 s u bjects).
Ra n d o mizati o n will be stratifie d b y st u d y ce nter.
S u bjects eli gi ble f or t he treat me nt m ust meet t he se verity criteria f or L C L a n d G L at baseli ne (i.e.
m o derate t o se vere L C L a n d G L  at ma xi m u m s mile a n d ma xi m u m fr o w n, res pecti vely). L C L s h o ul d 
be bilaterall y s ym metrical. Baseli ne wri n kle se verity deter mi nati o n will be base d o n b ot h 
i n vesti gat or a n d s u bject rati n gs usi n g t he 4- p oi nt p h ot o gra p hic scale of L C L se verity ( L C L-I L A; 
L C L -S L A) a n d t he 4- p oi nt p h ot o gra p hic scale of G L se verity ( G L-I L A) a n d t he s u bject 4 -p oi nt 
cate g orical scale ( G L- S L A).Title  D o c i d  
[ADDRESS_1103465] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 3 5 of 9 6F oll o wi n g treat me nt at b aseli ne, s u bjects will be m o nit ore d f or safet y a n d efficac y acc or di n g t o t he 
Sc he d ule of Assess me nts (Ta ble 2 ).
Ef ficac y assessme nts will i ncl u de ( Secti o n 7. 1 ):
I n vesti gat or 4- p oi nt P h ot o gra p hic Scale of L C L Se verit y  at  ma xi m u m 
s mile (In vesti gat or assess me nt [ L C L -I L A])
S u bject 4- p oi nt P h ot o gra p hic Scale of L C L Se verit y  at  ma xi m u m s mile 
(s u bject assess me nt [ LC L -S L A])
I n vesti gat or 4- p oi nt P h ot o gra p hic Scale of G L Se verit y at  ma xi m u m fr o w n 
(I n vesti gat or assess me nt [ G L-I L A])
S u bject Static 4- p oi nt Cate g orical Scale of G L Se verit y at ma xi m u m fr o w n (s u bject 
assess me nt [ G L-S L A])
Safet y  assess me nts will i ncl u de ( Secti o n 7. 2 ):
A Es
F oc use d p h ys ical e xa mi nati o n ( F P E)
Vital si g ns
E C G
La b orat or y safet y tests (c he mistr y a n d he mat ol o g y)
Pr o d ucti o n of n e utralizi n g a nti b o dies a gai nst Q M [ADDRESS_1103466] u d y tas ks b y treat me nt visit is o utli ne d i n Secti o n 8 a n d i n Ta ble 2 . I nf or mati o n re gar di n g cli nical 
s u p plies a n d treat me nt pr oce d ure are pr o vi de d i n Secti o n 6 .
4. C LI NI C A L S T U D Y D U R A TI O N A N D T E R MI N A TI O N
T he pla n ne d d urati o n of recr uit me nt (fr o m first s u bject first visit [ F S F V] t o last s u bject first visit 
[ LS F V]) is a p pr o xi matel y  [ADDRESS_1103467] visit ( L SL V) is a p pr o xi matel y
9. [ADDRESS_1103468] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103469] u d y ce nter (for e xa m ple, lac k of s u bject e nr oll me nt or n o n- c o m plia nce wit h cli nical st u d y pr ot oc ol, 
re g ulati o n, or G C P) or pre mat urel y s us pe n d t he cli nical st u d y (for e xa m ple, f or safety, st u d y pr o d uct
q ualit y , re g ulat or y, efficac y, or l o gistical reas o ns) at a n y ti me wit h a p pr o priate n otificati o n.
5. S E L E C TI O N A N D DI S P O SI TI O N O F C LI NI C A L S T U D Y P O P U L A TI O N
5. 1 N u m ber of S u bjects
As a scree n fail ure rate of a p pr o xi matel y  10 perce nt is a ntici pate d, a p pr o xi matel y  4 5 4 s u bjects will 
be scree ne d i n or der t o get 4 1 3 s u bjects e nr olle d i n a 2: 2: 2 : 1 rati o t o:
6 0 u nits Q M 1 1 1 4 -D P ( [ADDRESS_1103470] b o i n t he G L, 1 1 8 s u bjects),
5 0 u nits Q M 1 1 1 4 -D P ( [ADDRESS_1103471] b o i n t he L C L, 1 1 8 s u bjects),
1 1 0 u nits Q M 1 1 1 4 -D P ( 6 0 u nits i n t he L C L  a n d 5 0 u nits i n t he G L, 1 1 8 s u bjects), or
P lace b o i n b ot h t he LC L  a n d G L (5 9 s u bjects).
It is e x pecte d t hat eac h ce nter will recr uit a si milar n u m ber of s u bjects.
5. [ADDRESS_1103472] f ulfill all of t he f oll o wi n g criteria. T hese 
criteria are a p plica ble at b ot h scree ni n g a n d baseli ne u nless ot her wise s pecifie d. 
5. 2. 1 I ncl usi o n C riteri a
1. Male or fe male 1 8 ye ars of a ge or ol der .
2. M o derate t o se vere bilaterall y  sy m metrical L C L ( gra de 2 or 3 o n t he 4 -p oi nt P h ot o gra p hic Scale 
ra n gi n g fr o m 0 [ n o ne] t o 3 [se vere]) at ma xi m u m s mile as assesse d b y  the I n vesti gat or li ve 
assess me nt ( L C L -I L A).
3. B ilaterall y sy m metrical L C L gra de d as Le vel 2 or Le vel 3 o n t he 4- p oi nt P h ot o gra p hic Scale 
(ra n gi n g fr o m Le vel 0 t o Le vel 3) at ma xi m u m s mile as assesse d b y  t he s u bject li ve assess me nt 
( LC L -S L A).
4. M o derate t o se vere G L  (gra de 2 or 3 o n t he 4- p oi nt P h ot o gra p hic Scale ra n gi n g fr o m 0 [ no ne] 
t o 3 [se vere]) at ma xi m u m fr o w n as assesse d by t he I n vesti gat or ( G L -I L A).
5. M o derate t o se vere G L ( gra de 2 or 3 o n t he Static 4 -P oi nt Cate g orical Scale ra n gi n g fr o m 0 [ n o
wri n kles ] t o 3 [se vere wri n kles ]) at ma xi m u m fr o w n as assesse d by t he s u bject ( G L -S L A).Title  D o c i d  
[ADDRESS_1103473] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 3 7 of 9 66. Fe male of n o n -c hil d beari n g p ote ntial (i.e., p ost -me n o pa usal [a bse nce of me nstr ual blee di n g f or 
1 y ear pri or t o scree ni n g, wit h o ut a n y  ot her me dical reas o n], or has u n der g o ne h ysterect o m y or 
bilateral o o p h orect o m y ).
O R
Fe male of c hil d beari n g p ote ntial wit h a ne gati ve uri ne pre g na nc y test at scree ni n g a n d baseli ne, 
a n d a grees t o use a hi g hl y  effecti ve a n d a p pr o ve d c o ntrace pti ve met h o d f or t he d urati o n of t he 
st u d y. A hi g hly effecti ve met h o d of c o ntrace pti o n is defi ne d as:
Bilateral t u bal li gati o n;
C o m bi ne d (estr o ge n a n d pr o gester o ne c o ntai ni n g) oral, i ntra va gi nal or tra ns der mal 
c o ntrace pti ves t hat i n hi bit o v ulati o n as t he pri mar y  m o de of acti o n, o n a sta ble d ose f or at 
least 2 8 da ys pri or t o scree ni n g visit;
I ntra uteri ne de vice (I U D) i nserte d at least 28 da y s pri or t o scree ni n g visit; 
I ntra uteri ne h or m o ne-releasi n g sys te m;
Part ner vasect o mize d f or at least t hree m o nt hs pri or t o scree ni n g visit;
Pr o gest o ge n - o nly oral, i njecta ble or i m pla nta ble c o ntrace pti ves t hat i n hi bit o v ulati o n as 
t he pri mar y m o de of acti o n, o n a sta ble d ose f or at least 2 8 da ys pri or t o scree ni n g visit; or
Strict a bsti ne nce (i.e., refrai ni n g fr o m heter ose x ual i nterc o urse f or t he e ntire d urati o n of 
t he s u bject's partici pati o n i n t he st u d y).
7. Ti me a n d a bilit y  t o c o m plete t he st u d y a n d c om pl y  wit h i nstr ucti o ns.
8. U n dersta n ds t he st u d y re q uire me nts a n d si g ne d t he i nf or me d c o nse nt f or m (I C F).
5. 2. [ADDRESS_1103474] u d y ( ot her t ha n t he i n vesti gati o nal pr o d uct).
3. Fe male w h o is pre g na nt, breast fee di n g, or i nte n ds t o c o ncei ve a c hil d d uri n g t he st u d y
4. K n o w n aller g y or h y per se nsiti vit y to a n y c o m p o ne nt of t he i n vesti gati o nal pr o d uct ( Q M 1 1 1 4 -
D P) .
5. I na bilit y to s u bsta ntially re d uce t he a p peara nce of facial r hyt i des i n t he treat me nt area b y  
p h y sically s prea di n g t he m a part, as deter mi ne d b y t he I n vesti gat or.
6. Cli nicall y  si gnifica nt a b n or mal f oc use d p h ysical e xa mi nati o n fi n di n g(s) at scree ni n g or baseli ne 
visits , i n t he i n vesti gat or’s o pi [INVESTIGATOR_9384] o n.
7. E xcessi ve s ki n la xit y  i n t he treat me nt area or peri or bital area.
8. Pre vi o us use of a n y hya l ur o nic aci d s oft tiss ue a u g me ntati o n t hera py i n t he lateral ca nt hal or 
gla bella area wit hi n [ADDRESS_1103475] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 3 8 of 9 69. Pre vi o us s oft tiss ue a u g me ntati o n wit h a n y per ma ne nt ( n o n-bi o de gra da ble s uc h as silic o ne, 
p ol y acr yla mi de, etc.) or se mi-per ma ne nt (e. g., calci u m h y dr o x yl a patite, P ol y - L-Lactic aci d or 
p ol y met h y l-met hacr y late) pr o d uct; lifti n g t hrea ds, or a u t ol o g o us fat i n t he treat me nt area. 
[ADDRESS_1103476] or y , prese nce, or pre dis p ositi o n of e yeli d or e ye br o w pt osis ( hea vy e ye br o ws), a m bl yo pia 
(i.e., laz y eye ), or pre vi o us s ur ger y ar o u n d t he e ye t hat m a y  lea d t o t he a b o ve e ve nts, as 
deter mi ne d b y t he I n vesti gat or.
1 1. Mar ke d facial as y m metr y , e xcessi ve der mat oc halasis (i.e., e xcess of s ki n i n e yeli ds), or mar ke d 
peri oc ular or e y e br o w as ym metr y .
1 2. Prese nce of scar(s), pi[INVESTIGATOR_283954] n g(s), or tatt o os (i ncl u di n g micr o bla di n g of e ye br o w or e yeli ner) i n 
t he treat me nt area or ar o u n d t he t reat me nt area, t hat i n t he I nvesti gat or's o pi [INVESTIGATOR_9384] o n, ma y  i nterfere 
wit h st u d y  e val uati o ns.
[ADDRESS_1103477] hetic pr oce d ures (e. g. a blati ve s ki n 
res urfaci n g, laser treat me nt, micr o nee dli n g, or c he mical peel) i n t he pre vi o us 1 2 m o nt hs t hat, i n 
t he I nvesti gat or’s o pi [INVESTIGATOR_9384] o n, c o ul d i nterfere wit h st u d y injecti o ns a n d/ or assess me nts or e x p ose t he 
s u bject t o u n d ue ris k b y st u d y partici pati o n.
1 6. Pla n ne d facial s ur ger y, e ye s ur ger y (i ncl u di n g L A SI K pr oce d ure) or aest hetic pr oce d ures (e. g. 
a blati ve s ki n res urfaci n g, laser treat me nt, micr o nee dli n g, or c he mical peel i n t he u p per or 
mi dfacial area) d uri n g t he st u d y  peri o d.
[ADDRESS_1103478] has a n y  pri or or c urre nt ps yc hiatric ill ness (e. g. ps yc h osis, de pressi o n, a n xiet y), alc o h ol 
or dr u g a b use, or is ta ki n g a nti de pressa nt, a n xi ol ytic, or a nti ps yc h otic me dicati o n t hat, i n t he 
I n vesti gat or's o pi [INVESTIGATOR_9384] o n, c o ul d affect t he s u bject's safety a n d/ or t he c o n d uct or o utc o me of t he 
st u d y.
2 1. Ot her c o nc urre nt me dical c o n diti o ns, t hera p y or ot her c o n diti o n t hat i n t he I n vesti gat or's o pi [INVESTIGATOR_9384] o n 
w o ul d i nterfere wit h t he e val uati o n of t he st u d y me dicati o n safety or efficac y an d/ or p ut t he 
s u bject at ris k if he/s he partici pates t o t he st u dy.
[ADDRESS_1103479] u d y ce nter pers o n nel (e. g. pare nts, c hil dre n, 
si bli n gs, or s p o use), e m pl o yees or cl ose relati ves of e m pl o yees at t he S p o ns or c o m pa n y.Title  D o c i d  
[ADDRESS_1103480] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103481]’s 
st u d y file a n d electr o nic case re p ort f or m (e C R F) usi n g me dical ter mi n ol o g y .
5. [ADDRESS_1103482] o p pe d wit hi n t he 4 wee ks prece di n g t he 
scree ni n g visit or wit hi n ti mefra mes s pecifie d i n t he i ncl usi o n/excl usi o n criteria .
C o nc o mita nt t hera pi[INVESTIGATOR_799852] d as f oll o ws:
a n y e xisti n g t hera pi[INVESTIGATOR_014] o n g oi n g at t he ti me of t he scree ni n g visit,
a n y cha n ges t o e xisti n g t hera pi[INVESTIGATOR_014] (s uc h as c ha n ges i n d ose or f or m ulati o n) d uri n g t he c o urse 
of t he cli nical st u d y, or
a n y ne w t hera pi[INVESTIGATOR_21044] d b y t he s u bject si nce t he scree ni n g visit .  
5. 4. 2 C ate g ories
T he f oll o wi n g t w o cate g ories are t o be c o nsi dere d f or pre vi o us a n d c o nc o mita nt t hera pi[INVESTIGATOR_014]: 
Dr u gs i ncl u di n g b ut n ot li mite d t o, prescri pti o n, o ver -t he-c o u nter ( O T C), birt h c o ntr ol 
pi[INVESTIGATOR_3353]/ patc hes/ h or m o nal de vices, vita mi ns, her bal me dici n es/s u p ple me nts, a n d h o me o pat hic 
pre parati o ns.
Me dical a n d s ur gical pr oce d ures i ncl u di n g, b ut n ot li mite d t o, laser/ra diati o n pr oce d ures, 
der mal fillers (area of treat me nt s h o ul d be i n dicate d), X-ra ys, s ur geries, t o ot h e xtracti o ns.
5. 4. [ADDRESS_1103483]’s s o urce d oc u me nts a n d e C R Fs.
C o nc o mita nt t hera pi[INVESTIGATOR_22920] t o be re vie we d at eac h visit a n d u p date d i n t he s o urce d oc u me nts a n d 
e C R Fs as nee de d . 
A n y  ne w c o nc o mita nt t hera py or m o dificati o n of a n e xisti n g t hera py ma y be li n ke d t o a n A E.  A 
c orres p o n di n g A E for m s h o ul d be c o m plete d t o acc o u nt f or t he c ha n ge i n t hera py, e xce pt i n s o me 
cases s uc h as t hera p y use d f or pr o p h yl a xis, d ose m o dificati o n f or a c hr o nic c o n diti o n, etc.
5. 4. 4 A ut h orize d C o nc o mit a nt T her a pi[INVESTIGATOR_014]
U nless liste d i n pr o hi bite d c o nc o mita nt t hera pi[INVESTIGATOR_014] (see Secti o n 5. 4. 5 ), all are a ut h orize d.Title  D o c i d  
[ADDRESS_1103484] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 4 0 of 9 65. 4. 5 Pr o hi bite d C o nc o mit a nt T her a pi[INVESTIGATOR_014]
T he f oll o wi n g t hera pi[INVESTIGATOR_66491] o hi bite d beca use t he y ma y interfere wit h t he efficac y an d/ or safet y 
assess me nt of t he st u d y pr o d ucts :
B ot u li n u m t o xi n of a n y ser ot yp e .
A n y  ot her i n vesti gati o nal ne w dr u g or de vice.
A n y  a bs or ba ble (te m p orar y) or n o n-a bs or ba ble ( per ma ne nt) material i n t he treat me nt areas.
Facial aest hetic pr oce d ures (e. g., a blati ve s ki n res urfaci n g, laser treat me nt, micr o nee dli n g, 
p h ot o d y na mic t hera p y, tatt o oi n g or c he mical peel) or a n y ot her pr oce d ures i n t he treat me nt
area.
F acial s ur ger y or e ye s ur ger y (i ncl u di n g L A SI K pr oce d ure).
Me dicati o ns t hat affect ne ur o m usc ular tra ns missi o n s uc h as c urare -li ke de p olarizi n g a ge nts, 
li nc osa mi des, p ol ym y xi ns, a ntic h oli nesterases a n d a mi n o gl yc osi de a nti bi otics.
If a pr o hi bite d t hera p y bec o mes a necessar y treat me nt f or best cli nical i nterest of t he s u bject or d ue 
t o safety reas o n, t he Me dical M o nit or ( Secti o n 1 1. 9 ) s h o ul d be n otifie d , if ti me per mits, t o disc uss 
p ossi ble alter nati ves pri or t o a d mi nistrati o n of a pr o hi bite d t hera p y .
If a s u bject recei ves a pr o hi bite d t hera py d uri n g the cli nical st u d y, t he Me dical M o nit or ( Secti o n 
1 1. 9 ) s h o ul d be n otifie d t o disc uss t he s u bject’s c o nti n uati o n i n t he cli nical st u d y.
5. 5 Pr oce d ures/ Re as o ns f or S u bject D isc o nti n u ati o n
A n I n vesti gat or ma y  deci de t o disc o nti n ue a s u bject fr o m t he cli nical st u d y f or safet y reas o ns.
Alt h o u g h t he i m p orta nce of c o m pleti n g t he e ntire cli nical st u d y s h o ul d be e x plai ne d t o t he s u bject 
b y  t he cli nical st u d y pers o n nel, a n y  s u bject is free t o disc o nti n ue partici pati o n i n t his cli nical st u d y
at a n y ti me a n d f or w hate ver reas o n, s pecifie d or u ns pecifie d, a n d wit h o ut a n y prej u dice.  No 
c o nstrai nts are t o be i m p ose d o n t he s u bject, a n d w he n a p pr o priate, a su bject m a y  be treate d wit h 
ot her c o n ve nti o nal t hera p y  w he n cli nically i n dicate d. 
W he n a s u bject d oes n ot c o m plete t he cli nical st u d y, he/s he will be f ull y assesse d, if s uc h assess me nt 
is p ossi ble.  The pr oce d ures desi g nate d f or t he M o nt h 6/ E T visit s h o uld be c o m plete d f or all s u bjects 
disc o nti n ui n g t he cli nical st u d y a n d t he a p pr o priate e C R F s h o ul d be c o m plete d.
All disc o nti n uati o ns a n d t he reas o n f or disc o nti n uati o n are t o be d oc u me nte d b y t he I n vesti gat or o n 
t he e xit for m. F or disc o nti n uati o n d ue t o a n A E, t he A E for m is t o be c o m plete d. T he I n vesti gat or 
s h o ul d als o e ns ure t hat t he s u bject recei ves s uita ble t hera py f or t he A E.
P ote ntial reas o ns f or disc o nti n uati o n are liste d bel o w:
A d verse E ve nt: C o m plete a n A E f or m.Title  D o c i d  
[ADDRESS_1103485] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 4 1 of 9 6Wit h dra wal b y  
S u bject:I ncl u des c o nse nt wit h dra wal, s u bject rel ocati o n, sc he d ule c o nflicts, etc.  
E x plai n t he reas o n f or wit h dra wal i n t he c o m me nt secti o n of t he e C R F
exit f or m.
L ost t o 
F oll o w - u p:C o nfir me d wit h t w o d oc u me nte d p h o ne calls a n d a certifie d letter 
( deli ver y recei pt re q ueste d) wit h o ut a ns wer.  Ex plai n i n t he c o m me nt 
secti o n of t he e C R F e xit f or m.
Ot her: T his cate g or y is t o be use d f or a s u bject w h o disc o nti n ues d ue t o a 
reas o n ot her t ha n as s pecifie d i n t he pre defi ne d cate g ories a b o ve.  
E x plai n t he reas o n f or disc o nti n uati o n i n t he c o m me nt secti o n of t he 
e C R F exit f or m.
A s u bject w h o has bee n ra n d o mize d a n d assi g ne d a kit n u m ber/ra n d o mizati o n n u m ber ca n n ot be 
re place d b y  an ot her s u bject if he/s he disc o nti n ues t he cli nical st u d y f or a n y reas o n. A d diti o nal 
s u bjects c o ul d be e nr olle d (ra n d o mize d/assi g ne d t o treat me nt) i n or der t o attai n t he n u m ber of 
e val ua ble s u bjects.
Pre g na ncies occ urri n g d uri n g t he scree ni n g peri o d are c o nsi dere d scree n fail ures; t he y sh o ul d be 
rec or de d as s uc h i n t he e C R F a n d n o pre g na nc y  for m is t o be c o m plete d. I n case of a pre g na nc y 
occ urri n g after t he baseli ne visit, f oll o w t he pr oce d ures descri be d i n Secti o n 7. 2. 6. 2. [ADDRESS_1103486] u d y, b ut n o i n vasi ve pr oce d ure s h o ul d be c o n d ucte d (e. g. n o sa m ple ta ke n f or 
la b test).
T he S p o ns or ma y  als o deci de t o pre mat urel y ter mi nate or s us pe n d a s u bject’s partici pati o n i n t he 
cli nical st u d y.Title  D o c i d  
[ADDRESS_1103487] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103488] ( Q M 1 1 1 4-D P) will be s u p plie d as a sterile s ol uti o n for i njecti o n 
c o ntai ni n g t he dr u g s u bsta nce, Q M [ADDRESS_1103489] u g s u bsta nce is a B o N T T y pe A. Q M 1 1 1 4 -D S 
is dil ute d i n a b uffer s ol uti o n.  
At t he baseli ne visit, Q M 1 1 1 4 -D P will be a d mi nistere d per t he bli n de d ra n d o mizati o n assi g n me nt
as o ne of t he f oll o wi n g :
6 e q ual ali q u ots of 0. 1 m L i n eac h of t he i njecti o n sites i n t he LC L  areas f or a t otal v ol u me of 
0. 6 m L  ( 0. 3 m L per L C L treat me nt si de) of Q M 1 1 4-D P, or
5 e q ual ali q u ots of 0. 1 m L  in eac h of t he i njecti o n sites i n t he G L area f or a t otal v ol u me of 
0. 5 m L  of Q M 1 1 1 4-D P, or
[ADDRESS_1103490] b o will be s u p plie d as a b uffere d s ol uti o n f or i njecti o n c o ntai ni n g o nl y  the b uffer s ol uti o n of 
Q M 1 1 1 4 - D P; place b o d oes n ot c o ntai n acti ve dr u g s u bsta nce. 
At t he baseli ne visit, place b o will be a d mi nistere d per t he bli n de d ra n d o mizati o n assi g n me nt as
o ne of t he f oll o wi n g :
6 e q ual ali q u ots of 0. 1 m L i n eac h of t he i njecti o n sites i n t he L C L area s f or a t otal v ol u me of 
0. 6 m L  ( 0. 3 m L per L C L treat me nt si de) of place b o, or
[ADDRESS_1103491] b o, or
[ADDRESS_1103492] ore d at t he rec o m me n de d te m perat ure ( bet wee n 2° C a n d 8° C ; 3 6 
º F – 4 6 º F ). T he place b o pr o d uct s h o ul d n ot be fr oze n a n d s h o ul d be pr otecte d fr o m li g ht.Title  D o c i d  
[ADDRESS_1103493] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103494] a nce  Q M 1 1 1 4 -D S N/ A
I nter n al C o de Q M [ADDRESS_1103495] b o
P h ar m ace utic al F or m S ol uti o n f or i njecti o n S ol uti o n f or i njecti o n
C o nce ntr ati o n 1 0 0 u nits/ m L, b uffere d s ol uti o n N/ A , b uffer s ol uti o n
D os a ge 6 0 u nits
0. 6 m L t otal
0. 1 m L per L C L i njecti o n p oi nt
A N D/ O R
5 0 u nits 
0. 5 m L t otal
0. 1 m L per G L i njecti o n p oi ntN/ A
0. 6 m L t otal
0. 1 m L per L C L i njecti o n p oi nt
A N D/ O R
N/ A
0. [ADDRESS_1103496] I de ntific ati o n N u m ber ( SI N) 
Eac h st u d y partici pa nt w h o has si g ne d t he I C F will be e ntere d i nt o t he e C R F s yste m a n d a s u bject 
n u m ber will be assi g ne d via t he e C R F s yste m. F or t he d urati o n of t he st u d y, t he s u bject will be 
i de ntifie d usi n g t he s u bject n u m ber f or all d oc u me ntati o n a n d disc ussi o n.
S u bject n u m bers will c o nsist of t he st u d y ce nter n u m ber f oll o we d b y a c o nsec uti ve n u m ber starti n g 
wit h [ADDRESS_1103497] u d y partici pati o n, the reas o n f or scree n 
fail ure s h o ul d be s pecifie d. A scree n fail ure ca n n ot be re -scree ne d.
A l o g/listi n g s h o ul d be mai ntai ne d b y  eac h site f or all s u bjects w h o ha ve si g ne d t he I CF. T here 
s h o ul d be sufficie nt i nf or mati o n t o li n k t he e C R F t o a st u d y su bject’s s o urce d oc u me nts a n d me dical 
rec or ds.Title  D o c i d  
[ADDRESS_1103498] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103499] wit hi n 
t he Electr o nic Data Ca pt ure ( E D C) s ys te m. 
6. 1. 6 Kit N u m ber/ R a n d o miz ati o n N u m ber
A kit n u m ber /ra n d o mizati o n n u m ber , a u ni q ue n u m ber o n t he la bel of t he st u d y pr o d ucts, will be 
assi g ne d t o eac h eli gi ble s u bject at baseli ne.
Kit n u m ber/ra n d o mizati o n n u m ber will be all ocate d i n asce n di n g se q ue ntial or der t o eac h eli gi ble 
s u bject.
6. 1. [ADDRESS_1103500] is descri be d i n t he Mater ial Safet y Data 
S heet .
See als o Q M 1 1 1 4 - D P I n vesti gat ors Br oc h ure.1 2
6. 1. 7. 1 Tre at me nt Pr oce d ure
6. 1. 7. 1. 1 L ater al C a nt h us Are as
Pri or t o i njecti o n, t he treat me nt area s h o ul d be clea ne d wit h a s uita ble a ntise ptic s ol uti o n. A n 
a p pr o priatel y size d s yri n ge a n d nee dle (e. g., 3 0- 3 3 ga u ge nee dle ) s h o ul d be use d t o a d mi nister 
treat me nt.
At baseli ne, s u bjects will be ra n d o mize d t o recei ve treat me nt wit h Q M [ADDRESS_1103501] b o i n t he 
L C L.  A t otal d ose v ol u me of 0. 6 m L  di vi de d i nt o si x e q ual ali q u ots ( 0. 1 m L per i njecti o n site) will 
be a d m i nistere d i ntra m usc ularly i n t he lateral ca nt h us areas, 0. 3 m L  per si de. 
T here are t w o o pti o ns f or t he i njecti o n sites i n t he lateral ca nt h us areas; see Fi g ure [ADDRESS_1103502] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 4 5 of 9 6Fi g ure 2 I njecti o n Sites f or Tre ati n g L C L O pti o n 1
Fi g ure 3 I njecti o n Sites f or Tre ati n g L C L O pti o n 2
I njecti o ns s h o ul d be perf or me d at a 2 0- 3 0° a n gle t o t he s ki n, wit h be vel of nee dle ti p p oi nte d u p 
a n d a wa y fr o m t he e ye a n d ver y  su perficial. All i njecti o n p oi nts, t hree per si de, s h o ul d be at t he 
e xter nal part of t he or bic ularis oc uli m uscle a n d s ufficie ntl y far fr o m t he or bital ri m (at least 1 - 2 
c m). T he i njecti o n p oi nts s h o ul d be se parate d b y [ADDRESS_1103503] be ta ke n t o a v oi d i njecti n g t he z y g o matic us maj or/ mi n or m uscles t o a v oi d lateral 
m o ut h dr o p a n d as y m metrical s mile.Title  D o c i d  
[ADDRESS_1103504] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 4 6 of 9 66. 1. 7. 1. 2 Gl a bell ar Li nes
Pri or t o i njecti o n, t he treat me nt area s h o ul d be clea ne d wit h a s uita ble a ntise ptic s ol uti o n. A n 
a p pr o priatel y size d s yri n ge a n d nee dle (e. g., 3 0- 3 3 ga u ge nee dle ) s h o ul d be use d t o a d mi nister 
treat me nt.
At baseli ne, s u bjects will be ra n d o mize d t o recei ve treat me nt wit h Q M [ADDRESS_1103505] b o i n t he 
G L . Eac h treat me nt i ncl u des fi ve i ntra m usc ular (I M) i njecti o ns of e q ual v ol u me ( 0. 1 m L) 
a d mi nistere d at 5 i njecti o n sites i n t he gla bellar re gi o n ( 0. 5 m L  in t otal).  The i njecti o ns s h o ul d 
c o m me nce i n t he pr ocer us m uscle f oll o we d b y  the c orr u gat or s u percilii m uscles o n eac h si de, 
m o vi n g o ut war ds fr o m t he me dia n. All i njecti o ns s h o ul d be a p pr o xi matel y 1 c m a b o ve t he u p per 
or bital ri m a n d i nter nal t o t he mi d -p u pi[INVESTIGATOR_5778] y  li nes (Fi g ure 4 ).
Fi g ure [ADDRESS_1103506] of t he ne ur ot o x i n (e.g., e yeli d pt osis), t he i n vesti gat or 
s h o ul d use o ne t h u m b t o a p pl y press ure o n t he u p per or bital ri m w hile i njecti n g. It is reco m me n de d 
t hat i njecti o n is n ot cl oser t ha n [ADDRESS_1103507] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103508] will recei ve a si n gle treat me nt wit h Q M 1 1 1 4 -D P a n d/or place b o at t he baseli ne vis it.
T he treat me nts i n vesti gate d i n t his st u d y  are:
 6 0 U of Q M 1 1 1 4 -D P i n t he L C L
 5 0 U of Q M 1 1 1 4 -D P i n t he G L
 Place b o
6. [ADDRESS_1103509] article disclai mer (“Ca uti o n: Ne w Dr u g - Li mite d b y  
Fe deral ( or U nite d States) la w t o i n vesti gati o nal use.”)
6. [ADDRESS_1103510] u d y pr o d ucts recei ve d fr o m t he S p o ns or ’s desi g nee , 
a n d t he ret ur n t o t he S p o ns or ’s desi g nee for dis p osal of u n use d st u d y  pr o d ucts .
All st u d y  pr o d ucts se nt t o t he In vesti gat or/I nstit uti o n will be acc o u nte d f or a n d n o u na ut h orize d use 
is per mitte d.
6. 3. [ADDRESS_1103511] ora ge 
c o n diti o ns s pecifie d b y t he S p o ns or (see Ta ble 3 ).
6. 3. [ADDRESS_1103512] be re p orte d t o t he S p o ns or/ C R O a n d 
pr o perl y d oc u me nte d.Title  D o c i d  
[ADDRESS_1103513] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C CI
C O N FI D E N TI A L
Pa ge 4 8 of 9 6I n t he e ve nt of earl y ter mi nati o n/s us pe nsi o n of t he cli nical st u d y, a ra pi d recall of st u d y pr o d ucts
will be i nitiate d.  
U n use d or e x pi[INVESTIGATOR_1312] d st u d y pr o d uct will be ret ur ne d f or destr ucti o n t o t he S p o ns or re prese ntati ve at 
ti me p oi nts a p pr o ve d b y t he S p o ns or.
6. 3. [ADDRESS_1103514] Q ualit y c o m plai nts ( P Q Cs) s h o ul d be re p orte d t o t he Safet y  e-mail liste d i n Secti o n [ADDRESS_1103515]; q ualit y  iss ue f or a pr o d uct 
relatin g t o its prese ntati o n or use, i de ntifie d b y  a su bject, a practiti o ner or In vesti gat or site pers o n nel, 
a distri b ut or, or a n y o ne else i n v ol ve d i n cli nical s u p plies ha n dli n g. E xa m ples ma y  incl u de b ut are 
n ot li mite d t o a p peara nce iss ues, o d or, da ma ge d st o p pers, l o w fills, a n d f orei g n matter i n t he pr o d uct. 
T hese c o m plai nts m a y  or m a y  not re prese nt a p ote ntial ris k t o t he s u bject. A P Q C f or m m ust be 
c o m plete d b y t he st u d y ce nter pers o n nel a n d f or war de d t o t he S p o ns or or desi g nee wit hi n [ADDRESS_1103516] details are pr o vi de d i n t he I n vesti gat or’s site file.
6. [ADDRESS_1103517]'s st u d y pr o d uct assi g n me nt (i.e., Q M 1 1 1 4 -D P a n d/ or place b o). Place b o 
is i de ntical i n a p peara nce t o Q M [ADDRESS_1103518] u d y pr o d ucts will be a d mi nistere d i n 
e xactl y t he sa me wa y.
A n u n- bli n de d statisticia n will ge nerate t he ra n d o mizati o n sc he d ule; h o we ver, he/s he will n ot b e 
i n v ol ve d i n a n y ot her as pect of t he st u d y pri or t o data base l oc k.Title  D o c i d  
[ADDRESS_1103519] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 4 9 of 9 6T he S p o ns or’s staff or desi g nees directl y i n v ol ve d i n cli nical o perati o ns ma na ge me nt, data 
ma na ge me nt, a n d statistical e val uati o n of t he st u d y will re mai n bli n de d u ntil t he data base is l oc ke d, 
u nless e mer ge nc y  u n bli n di n g is re q uire d. 
6. 4. 1 Verific ati o n of B li n di n g
T he S p o ns or’s staff or desi g nees will assess a n d verif y  mai nte na nce of t he st u d y bli n d d uri n g t he 
st u d y t hr o u g h r o uti ne m o nit ori n g visits. 
6. 4. [ADDRESS_1103520] u d y ma y  be re q uire d f or t hera pe utic or f or re g ulat or y 
reas o ns (f or e x pe dite d safet y re p orti n g).
A bli n d -brea k s yste m will b e a vaila ble f or I n vesti gat ors.  I n s uc h a n e mer ge nc y, t he I n vesti gat or 
will o nl y  brea k t he bli n d f or t he s u bject i n v ol ve d.
T he I n vesti gat or m ust n otif y  the S p o ns or i m me diatel y in t he e ve nt of s uc h a n e mer gen c y  (see c o ntact 
details i n Secti o n 7. 2. 6. 2. 2 ).  If p ossi ble, t he I n vesti gat or s h o ul d n otif y t he S p o ns or bef ore brea ki n g 
t he bli n d i n or der t o disc uss t his decisi o n wit h t he S p o ns or.  The I nvesti gat or is re q uire d t o d oc u me nt 
eac h case of e mer ge nc y u n bli n di n g a n d i nf or m t he S p o ns or i m me diatel y.
7. C LI NI C A L S T U D Y A S S E S S M E N T
7. 1 Effic ac y A ssess me nts
7. 1. 1 I n vesti g at or 4- p oi nt P h ot o gr a p hic Sc ale of L ater al C a nt h al Li ne Se verit y
( L C L-I L A)
T he vali date d I n vesti gat or 4- p oi nt P h ot o gra p hic Scale of Lateral Ca nt hal Li ne Se verit y ( L C L-I L A) 
(A p pe n di x 1 ), de vel o pe d b y  Gal der ma, i ncl u des t w o gra di n g s yste ms: o ne f or t he In vesti gat or li ve 
assess me nts at ma xi m u m s mile, . 
T he scale re prese nts L C L se verities fr o m n o ne ( gra de 0), mil d ( gra de 1), m o derate ( gra de 2) , t o 
se vere ( gra de 3). E ac h gra de is als o de pi[INVESTIGATOR_21043] d b y a n i n di vi d ual p h ot o gra p h a n d descri pti ve te xt. T he 
I n vesti gat ors will be trai ne d o n t he use of t he L C L- I L A.
T he In vesti gat ors will use t he L C L- I L A f or direct, li ve c o m paris o n wit h t he s u bject’s face f or
gra di n g L C L se verity a t scree ni n g, baseli ne ( pri or t o treat me nt), a n d at all p ost -treat me nt visits.  Left 
a n d ri g ht L C L s h o ul d be assesse d se paratel y at  ma xi m u m s mile. Title  D o c i d  
[ADDRESS_1103521] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103522] 4- p oi nt P h ot o gr a p hic Sc ale of L ater al C a nt h al Li ne Se ver it y ( L C L-S L A )
T he vali date d S u bject 4- p oi nt P h ot o gra p hic Scale of Lat eral Ca nt hal Li ne Se verit y ( LC L -S L A) 
(A p pe n di x 2 ), de vel o pe d b y  Gal der ma, i ncl u des t w o gra di n g s yste ms: o ne f or t he s u bject’s li ve 
assess me nts at ma xi m u m s mile, . T he 
scale re prese nts L C L se verities fr o m Le vel 0, Le vel 1, Le vel 2 , t o Le vel 3. E ac h gra de is als o 
de pi[INVESTIGATOR_21043] d b y a n i n di vi d ual p h ot o gra p h a n d descri pti ve te xt. S u bjects will be trai ne d o n t he use of t he 
L C L- S L A. 
S u bjects ma ke t heir assess me nts i n de pe n de ntly of t he I n vesti gat or’s assess me nt. S u bjects will 
e val uate t heir L C L se verit y (left a n d ri g ht si de se parately) at  ma xi m u m s mile, 
res pecti vely, at scree ni n g, baseli ne ( pri or t o treat me nt), a n d at all p ost-treat me nt visits.  
7. 1. 3 I n vesti g at or 4- p oi nt P h ot o gr a p hic Sc ale of Gl a bell ar Li ne Se verit y ( G L-I L A)
T he vali date d I n vesti gat or 4- p oi nt P h ot o gra p hic Scale of Gla b ellar Li ne Se verit y  ( G L-I L A) 
(A p pe n di x 3 ) i ncl u des t w o gra di n g s yste ms: o ne f or I n vesti gat or li ve assess me nts at ma xi m u m 
fr o w n, . T he scale re prese nts t he se verity o f G L fr o m 
n o ne ( gra de 0), mil d ( gra de 1), m o derate ( gra de 2) t o se vere ( gra de 3). Eac h gra de is als o de pi[INVESTIGATOR_21043] d 
b y  an i n di vi d ual p h ot o gra p h a n d a descri pti ve te xt. T he I nvesti gat ors will be trai ne d o n t he use of 
t he 4-p oi nt P h ot o gra p hic Scale.
T he I n vesti gat ors will use t he 4- p oi nt P h ot o gra p hic Scale s f or direct, li ve c o m paris o n wit h t he 
s u bject’s face at  at ma xi m u m fr o w n at scree ni n g, baseli ne ( pri or t o treat me nt), a n d at all 
p ost -treat me nt visits.
7. 1. [ADDRESS_1103523] atic 4 -p oi nt C ate g oric al Sc ale of Gl a bell ar Li ne Se verit y ( G L-S L A)
S u bjects will ma ke t heir assess me nt of gla bellar li ne se verity i n de pe n de ntl y of t he I n vesti gat or’s 
assess me nt. S u bjects will be as ke d t o e val uate t heir G L at ma xi m u m fr o w n at scree ni n g, baseli ne 
( pri or t o treat me nt), a n d at all p ost -treat me nt visits usi n g t he f oll o wi n g Static 4- P oi nt Cate g orical 
Scale .
Gr a de Se verit y of Gl a bell ar Li nes Descri pti o n
[ADDRESS_1103524] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103525] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C CI
C O N FI D E N TI A L
Pa ge 5 2 of 9 67. 2 S afet y A ssess me nts
S afet y assess me nt will be c o n d ucte d f or all s u bjects at t he ti me p oi nts i n dicate d i n Sc he d ule of 
Assess me nts (Ta ble 2 ).  Safet y  para meters i ncl u de a n e val uati o n of A Es ,  vital si g ns, E C G, 
la b orat or y safety tests (c he mistr y a n d he mat ol o g y), a n d ne utralizi n g a nti b o d y pr o d ucti o n .
7. 2. 1 F oc use d P h ysic al E x a mi n ati o n ( F P E)
At t he ti me p oi nts i n dicate d i n t he Sc he d ule of Assess me nts (Ta ble 2 ), t he I n vesti gat or or desi g nee 
will perf or m a p h y sical e xa mi nati o n of t he s u bject t hat i ncl u des t he face, hea d, a n d nec k. F urt h er 
details are pr o vi de d i n A p pe n di x [ADDRESS_1103526]’s s ym pt o ms a n d si g ns (A p pe n di x 7 ). Directe d
q uesti o ni n g a n d e xa mi nati o n will t he n be perf or me d as a p pr o priate.
T he I nvesti gat or m a y  ch o ose t o i n vesti gate a n y ot her si g n t hat he/s he o bser ves d uri n g t he p h y sical 
e xa mi nati o n. A b n or malities n ote d pre -i njecti o n, i.e. at t he scree ni n g/ baseli ne visits, s h o ul d be 
rec or de d as me dical hist or y a n d ab n or malities n ote d p ost -i njecti o n s h o ul d be rec or de d as A Es.
7. 2. 2 Vit al Si g ns
At t he ti me p oi nts i n dicate d i n t he Sc he d ule of Assess me nts (Ta ble 2 ), eval uati o n of vital si g ns s hall 
be perf or me d after a p pr o xi matel y [ADDRESS_1103527] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103528] or y f or m.
F or a n y cli nicall y si g nifica nt c ha n ges fr o m t he baseli ne visit, a n A E is t o be rec or de d.
7. 2. 3 Electr oc ar di o gr a m ( E C G)
T he [ADDRESS_1103529] or y  for m. F or 
a n y cli nicall y si g nifica nt c ha n ges fr o m baseli ne, a n A E is t o be rec or de d.
T he I n vesti gat or a n d Me dical M o nit or will be alerte d (e g, e mail) f or E C Gs t hat are i de ntifie d as 
“a b n or mal, cli nicall y si g nifica nt” b y t he ce ntral E C G la b orat or y.
7. 2. 4 L a b or at or y S afet y Tests
Bl o o d sa m ples will be c ollecte d at baseli ne ( pri or t o treat me nt) a n d at M o nt h 6/ E T, a n d se nt t o a 
ce ntral la b orat or y for a nal y sis. I nstr ucti o ns f or bl o o d sa m pli n g are detaile d i n a se parate la b orat or y 
ma n ual.
T he f oll o wi n g la b orat or y safet y tests s hall be perf or me d:
He mat ol o g y : W hite bl o o d cell ( W B C) c o u nt wit h differe n tial, re d bl o o d cell ( R B C) c o u nt, 
hae m o gl o bi n ( H b), he mat ocrit ( hct), a n d platelet c o u nt ( Plt)
Bl o o d c he mistr y: Creati ni ne, urea nitr o ge n, ga m ma gl uta m yl  tra nsferase ( G G T), al kali ne 
p h os p hatase ( A L P), as partate a mi n otra nsferase ( A S T = S G O T), ala ni ne a mi n otransferase 
( A L T = S G P T), a n d bilir u bi n (t otal a n d c o nj u gate d)
T he In vesti gat or or a me dicall y q ualifie d s u b-In vesti gat or m ust re vie w a n d e val uate la b orat or y 
val ues f or eac h s u bject i n a ti mel y ma n ner.  Th e In vesti gat or or desi g nee will i nitial a n d date all 
la borat or y  re p orts a n d n ote o n t he re p ort w het her or n ot a n o ut of ra n ge la b orat or y val ue is cli nicall y 
si g nifica nt. A n o ut of ra n ge la b orat or y  val ue s h o ul d be c o nsi dere d as cli nicall y si gnifica nt if eit her 
of t he f oll o wi n g c o n diti o ns is met:
T he a b n or malit y s u g gests a disease a n d/ or or ga n t o xicit y.
T he a b n or malit y is of a de gree t hat re q uires a d diti o nal acti ve ma na ge me nt, e. g. cl ose 
o bser vati o n, m ore fre q ue nt f oll o w- u p assess me nts, or f urt her dia g n ostic i n vesti gati o nTitle  D o c i d  
[ADDRESS_1103530] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103531] or y (re p ort a dia g n osis rat her t ha n a n i n di vi d ual la b orat or y para meter 
a b n or malit y w he ne ver p ossi ble).   
All cli nicall y si gnifica nt o ut of ra n ge la b orat or y val ues f or bl o o d sa m ples c ollecte d after baseli ne 
are t o be re p orte d as a n A E if t his a b n or malit y was n ot prese nt at t he baseli ne visit or is assesse d as 
ha vi n g w orse ne d si nce t he scree ni n g visit (i.e., t here is a si g nifica nt c ha n ge fr o m baseli ne ). 
F or A Es, w he ne ver p ossi ble, t he I n vesti gat or is t o pr o vi de a dia g n osi s rat her t ha n t o re p ort i n di vi d ual 
la b orat or y a b n or malities.
7. 2. 5  Ne utr alizi n g A nti b o d y Testi n g
S u bjects will ha ve b l o o d sa m ples ta ke n at baseli ne pri or t o treat me nt , M o nt h 1, a n d M o nt h 6/ E T f or 
meas ure me nt of ser u m ne utralizi n g a nti b o d y testi n g a gai nst Q M [ADDRESS_1103532] e nr oll me nt visit, t he I nvesti gat or ( or s u b-I n vesti gat or) will q uesti o n t he s u bject a b o ut 
A Es usi n g a n o pe n n o n- pers uasi ve q uesti o n t o elicit re p orti n g of A Es, f or e xa m ple “ Ha ve y o u 
n otice d a n y c ha n ge i n y o ur healt h si nce t he last visit?”  Ad diti o nal q uesti o ni n g a n d e xa mi nati o n will 
t he n be perf or me d as a p pr o priate.
7. 2. 6. 1 Defi niti o ns
7. 2. 6. 1. 1 A dverse E ve nts ( A E)
Acc or di n g t o I CH E [ADDRESS_1103533] a n d w hic h d oes n ot necessarily ha ve a 
ca usal relati o ns hi p wit h t his treat me nt. A n A E ca n t heref ore be a n y u nfa v ora ble a n d u ni nte n de d si g n 
(i ncl u di n g a n a b n or mal la b orat or y fi n di n g), sy m pt o m, or disease te m p orall y ass ociate d wit h t he use Title  D o c i d  
[ADDRESS_1103534] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 5 5 of 9 6of a me dici nal (i n vesti gati o nal) pr o d uct, w het her or n ot relate d t o t he me dici nal (in vesti gati o nal) 
pr o d uct.
T h us, a n y ne w si g n, s y m pt o m or disease, or a n y cli nicall y si g nifica nt w orse ni n g of a n e xisti n g si g n, 
s ym pt o m or disease (i ncl u di n g ne w e pis o des of a c hr o nic disease [e. g., h a y  fe ver, aller g y]) c o m pare d 
t o t he c o n diti o n at t he first visit, s h o ul d be c o nsi dere d as a n A E. Lac k of efficac y is n ot c o nsi dere d 
as a n A E.
N otes:
T here s h o ul d be a n atte m pt t o re p ort a dia g n osis rat her t ha n t he si g ns, s y m pt o ms or a b n or mal 
la b orat or y val ues ass ociate d wit h t he re p ort of a n A E. H o we ver, a dia g n osis s h o ul d be re p orte d 
o nl y  if, i n t he In vesti gat or’s j u d g me nt, it is relati vel y  certai n. Ot her wise, sy m pt o ms, si g ns, or 
la b orat or y val ues s h o ul d be use d t o descri be t he A E.
Pre g na nc y  is n ot t o be c o nsi dere d as a n A E; h o we ver, is a n i m p orta nt me dical e ve nt t hat m ust 
be m o nit ore d as descri be d i n Secti o n 7. 2. 6. 2. 3 .
T he effects of all B o N T pr o d ucts ma y  s prea d fr o m t he area of i njecti o n t o pr o d uce s ym pt o ms 
c o nsiste nt wit h B o N T effects. T hese s ym pt o ms ha ve bee n re p orte d h o urs t o wee ks after 
i njecti o n. Re m ote s prea d of t o xi n t hat affects s wall o wi n g a n d breat hi n g ca n be life t hreate ni n g, 
a n d t here ha ve bee n re p orts of deat h. T he ris k of s y m pt o ms is i ncrease d i n s u bjects w h o ha ve 
u n derl y i n g c o n diti o ns (e. g. dis or ders of t he ne ur o m usc ular j u ncti o n) that w o ul d pre dis p ose 
t he m t o t hese sy m pt o ms. B o N T is c o ntrai n dicate d i n i n di vi d uals wit h k n o w n h y perse nsiti vit y 
t o a n y B o N T pre parati o n or t o a n y  of t he c o m p o ne nts i n t he f or m ulati o n. 
7. 2. 6. 1. 2 Tre at me nt E mer ge nt A dverse Eve nt ( T E A E)
A T E A E is a n e ve nt t hat e mer ges d uri n g treat me nt, ha vi n g bee n a bse nt pre -treat me nt, or w orse ns 
relati ve t o t he pretreat me nt state.
7. 2. 6. 1. 3 Seri o us A dverse E ve nts ( S A E)
A S A E is a n y u nt o war d me dical occ urre nce t hat at a n y  d ose:
Res ults i n deat h,
Is life-t hreate ni n g,
Re q uires i n patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_1314] o n,
Res ults i n persiste nt or si g nifica nt disa bilit y /i nca pacit y, or
Is a c o n ge nital a n o maly/ birt h defect.
I m p orta nt me dical e ve nts t hat ma y n ot res ult i n deat h, be life-t hreate ni n g, or re q uire h os pi[INVESTIGATOR_1314] o n 
m a y be c o nsi dere d a n S A E w he n, base d u p o n a p pr o priate me dical j u d g me nt, t he y ma y je o par dize 
t he safet y of t he s u bject, a n d m a y  re q uire me dical or s ur gical i nter ve nti o n t o pre ve nt o ne of t he 
o utc o mes liste d i n t his defi niti o n.  E xa m ples of s uc h e ve nts are i n te nsi ve treat me nt i n a n e mer ge nc y 
r o o m or at h o me f or aller gic br o nc h os pas m, bl o o d d y scrasia, or c o n v ulsi o ns t hat d o n ot res ult i n 
h os pi[INVESTIGATOR_1314] o n.Title  D o c i d  
[ADDRESS_1103535] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 5 6 of 9 6N ote: T he ter m “life-t hreate ni n g” refers t o a n e ve nt i n w hic h t he s u bject was at ris k of deat h at t he 
ti me o f t he e ve nt; it d oes n ot refer t o a n e ve nt w hic h h y p ot heticall y mi g ht ha ve ca use d deat h if it 
were m ore se vere.
I n patie nt h os pi[INVESTIGATOR_1314] o n is c o nsi dere d t o ha ve occ urre d if t he s u bject has ha d t o sta y for a ni g ht at 
t he h os pi[INVESTIGATOR_307].  T he criteri o n f or pr ol o n gati o n of h os pi[INVESTIGATOR_1314] o n is als o defi ne d as a n e xtra ni g ht at t he 
h os pi[INVESTIGATOR_307].  Hos pi[INVESTIGATOR_1314] o n ma y  not c o nstit ute s ufficie nt gr o u n ds t o be c o nsi dere d as a n S A E if it is 
s olel y for t he p ur p ose of a dia g n ostic test(s) (e ve n if relate d t o a n A E), electi ve h os pit alizati o n f or 
a n i nter ve nti o n t hat was alrea d y pla n ne d bef ore s u bject e nr ol me nt i n t he cli nical st u d y, a d missi o n 
t o a da y -care facilit y, s ocial a d missi o n (e. g., if t he s u bject has n o place t o slee p), or a d mi nistrati ve 
a d missi o n (e. g., f or a ye arl y e xa mi nati o n).
7. 2. 6. 1. [ADDRESS_1103536] i nf or mati o n (e. g., I n vesti gat or’s Br oc h ure 
f or a n u na p pr o ve d i n vesti gati o nal pr o d uct or t he me dici nal pac ka ge i nsert/s u m mar y of pr o d uct 
c haracteristics f or a n a p pr o ve d i n vesti gati o nal pr o d uct).
7. 2. 6. 1. [ADDRESS_1103537]’s partici pati o n.
T he S p o ns or s h o ul d be i nf or me d if t he I n vesti gat or bec o mes a ware of a n y u n us ual safet y 
i nf or mati o n or a n y safet y inf or mat i o n t hat a p pears t o be dr u g -relate d i n v ol vi n g a s u bject w h o has 
partici pate d i n a cli nical st u d y, e ve n after a s u bject has c o m plete d t he cli nical st u d y.  
7. 2. 6. 1. [ADDRESS_1103538] a p pr o priate acc or di n g t o his / her me dical 
j u d g me nt.
Mil d A ware ness of si g ns or s y m pt o m, b ut easil y  t olerate d.
M o der ate Disc o mf ort, e n o u g h t o ca use i nterfere nce wit h us ual acti vit y.
Se vere I nca pacitati n g wit h i na bilit y t o w or k or perf or m us ual acti vit y .
7. 2. 6. 1. [ADDRESS_1103539] a n d/ or C li nic al St u dy P r oce d ure
T he I nvesti gat or is t o deter mi ne w het her t here is a reas o na ble ca usal relati o ns hi p bet wee n t he 
occ urre nce of t he A E a n d e x p os ure t o t he st u d y  pr o d uct a n d/ or cli nical st u d y pr oce d ure .Title  D o c i d  
[ADDRESS_1103540] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103541] ors s uc h as c o-me dicati o n or c o nc urre nt dis eases.
T he e x pressi o n “reas o na ble ca usal relati o ns hi p” is mea nt t o c o n ve y  i n ge neral t hat t here are facts or 
ar g u me nts t o s u g gest a ca usal relati o ns hi p (I C H E 2 A, Secti o n III A 1).
T he relati o ns hi p assess me nt f or a n A E is t o be c o m plete d usi n g t he f oll o wi n g defi niti o ns as a 
g ui deli ne:
Re as o n a ble P ossi bilit y: Acc or di n g t o t he re p orti n g I n vesti gat or, t here is a reas o na ble p ossi bilit y  
(i.e., s u g gesti ve e vi de nce or ar g u me nts) t hat t here is a ca usal relati o ns hi p irres pecti ve of t he d ose 
a d mi nistere d bet wee n:
T he s t u d y pr o d uct ( acti ve or place b o ) a n d t he A E .
T he cli nical st u d y pr ot oc ol pr oce d ure (e. g., br uisi n g or mar ks fr o m bl o o d dra ws, i njecti o n 
relate d tra u ma, etc.) a n d t he A E .
A t w o -p oi nt scale ( Yes or N o res p o nse) s hall be use d f or t he ca usalit y assess me nt. T h e I n vesti gat or 
s hall be as ke d t o i n dicate a res p o nse t o eac h of t he f oll o wi n g q uesti o ns i n t he e C R F:
“ D o y o u c o nsi der t hat t here is a reas o na ble p ossi bilit y that t he e ve nt ma y ha ve bee n ca use d b y 
t he st u d y pr o d uct?”, a n d 
“ D o y o u c o nsi der t hat t here is a r eas o na ble p ossi bilit y that t he e ve nt ma y ha ve bee n ca use d b y 
t he st u d y pr o d uct i njecti o n pr oce d ure?”
If a ny of t hese q uesti o ns is a ns were d Yes, t he A E is c o nsi dere d relate d. 
N o Re as o n a ble P ossi bilit y: N o s u g gesti ve e vi de nce or ar g u me nts ca n be i de ntifie d re gar di n g a 
ca usal relati o ns hi p bet wee n t he st u d y  pr o d uct or t he cli nical st u d y pr ot oc ol pr oce d ure a n d t he A E.
7. 2. 6. [ADDRESS_1103542] -e nr oll me nt visit, t he I nvesti gat or ( or s u b-I nvesti gat or) will q uesti o n t he s u bject a b o ut 
A Es usi n g a n o pe n n o n- pers uasi ve q uesti o n t o elicit re p orti n g of A Es, f or e xa m ple “ Ha ve y o u 
n o tice d a n y c ha n ge i n y o ur healt h si nce t he last visit?”  Directe d q uesti o ni n g a n d e xa mi nati o n will 
t he n be perf or me d as a p pr o priate. 
A n y  A E occ urri n g d uri n g t he A E re p orti n g peri o d, w het her it is relate d t o t he st u d y pr o d uct or n ot, 
will be rec or de d i m me diatel y in t he s o urce d oc u me nt, a n d descri be d o n t he A E f or m of t he e C R F
al o n g wit h t he date of o nset, se verit y, relati o ns hi p t o t he st u d y pr o d uct , a n d o utc o me, wit h o ut 
o mitti n g a n y re q ueste d a n d k n o w n i nf or mati o n.  Ad diti o nal i nf or mati o n will be re q ueste d u n der 
certai n circ u msta nces.  Title  D o c i d  
[ADDRESS_1103543] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103544]’s st u d y  file.  If necessar y 
a n d a p pr o ve d b y  the s u bject or t heir le gal healt h care re prese ntati ve, t he I n vesti gat or m a y  co ntact 
t he s u bject’s pers o nal p h ysicia n or ot her healt h care pr o vi der(s) t o o btai n f urt her details.
F or S A Es (see Secti o n 7. 2. 6. 2. 2 ) a n d pre g na ncies (see Secti o n 7. 2. 6. 2. 3 ), t he S p o ns or is t o be 
i nf or me d i m me diatel y by e -mail.  The e ve nt m ust be re p orte d b y  to t he Safet y  e mail wit hi n 2 4 h o urs 
of recei pt of t he i nf or mati o n (c o ntact details i n Secti o n 7. 2. 6. 2. 2 ).
7. 2. 6. 2. [ADDRESS_1103545] d o t he f oll o wi n g:
1. Ta ke pr o m pt a n d a p pr o priate me dical acti o n, if necessar y .  The safety o f t he s u bject is t he first 
pri orit y .
2. E ns ure t hat t he e ve nt is classifie d as a n S A E ( Secti o n 7. 2. 6. 1. 3 ).
3. C o m plete t he A E f or m pr o vi de d i n t he e C R F as full y  as p ossi ble.
Pri nt a n d c o m plete t he S A E f or m.  E-mail t he c o m plete d f or m, acc o m pa nie d b y  an y  ot her 
rele va nt i nf or mati o n or a n o n ymize d me dical rec or ds (e. g., la b orat or y test res ults) wit hi n 
[ADDRESS_1103546] u gs /thera pi[INVESTIGATOR_014] f or m, me dical a n d s ur gical pr oce d ures f or m, a n d A E pa ges 
of t he e C R F m ust be c o m plete d a n d a vaila ble f or re vie w i n t he E D C s y ste m at t he ti me of t he 
re p ort.
4. I m me diatel y se n d t he c o m plete d S A E re p ort f or m t o t he Safet y  e-mail a n d disc uss furt her 
acti o ns t o be ta ke n.
E- mail: 
A d diti o nal c o ntact details are pr o vi de d i n t he I n vesti gat or’s site file.
5. M o nit or a n d rec or d t he pr o gress of t he e ve nt u ntil it res ol ves or reac hes a cli nicall y sta ble 
o utc o me, wit h or wit h o ut se q uelae.  For all a d diti o nal f oll o w- u p e val uati o ns, se n d all 
a d diti o nal f oll o w- u p i nf or mati o n o n t he S A E t o t he Safet y e-mail wit hi n [ADDRESS_1103547] oril y res ol ve d.
6. O btai n a n d mai ntai n i n his/ her files all perti ne nt me dical rec or ds a n d i nf or mati o n re gar di n g 
t he S A E.Title  D o c i d  
[ADDRESS_1103548] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103549] y wit h 
c o u ntr y s pecific re g ulat or y re q uire me nts relati n g t o safet y re p orti n g t o re g ulat or y aut h orities, 
I nstit uti o nal Re vie w B oar ds (IR Bs ), a n d In vesti gat ors. I n vesti gat or safet y re p orts are pre pare d 
f or S us pecte d U ne x pecte d Seri o us A d verse Reacti o ns ( S U S A Rs) acc or di n g t o l ocal re g ulat or y 
re q uire me nts a n d t he S p o ns or p olic y  an d are f or war de d t o In vesti gat ors as necessar y . A n 
In vesti gat or w h o recei ves a n In vesti gat or safety re p ort descri bi n g a S A E(s) or ot her s pecific 
safety i nf or mati o n (e. g., s u m mar y or listi n g of S A Es) fr o m t he S p o ns or will file it wit h t he 
I n vesti gat or’s Br o c h ure (I B) a n d will n otif y  the I RB, if a p pr o priate acc or di n g t o l ocal 
re q uire me nts.
9. C o m pl y  wit h t he a p plica ble re g ulat or y re q uire me nt(s) relate d t o t he re p orti n g of S A Es t o t he 
I RB.
7. 2. 6. 2. [ADDRESS_1103550] be m o nit ore d u ntil its o utc o me i n or der t o e ns ure t he c o m plete c ollecti o n of 
safety data.
S u bjects w h o bec o me pre g na nt d uri n g t he scree ni n g peri o d are c o nsi dere d as scree ni n g fail ures; 
t he y are rec or de d as s uc h i n t he e C R F a n d n o pre g na nc y f or m is t o be c o m plete d.
If a s u bject bec o mes pre g na nt after t he scree ni n g peri o d, t he I n vesti gat or is t o d o t he f oll o wi n g:
1. T he s u bject d oes n ot nee d t o be wit h dra w n fr o m t he cli nical st u d y, i.e. s he ma y  co nti n ue t o 
atte n d t he pla n ne d st u d y visits, b ut n o i n vasi ve pr oce d ure s h o ul d be c o n d ucte d (e. g. n o sa m ple 
ta ke n f or la b test).
2. C o m plete t he Pre g na nc y Re p ort Part A as f ull y as p ossi ble.  Se n d t he f or m wit hi n 2 4 h o urs of 
recei pt of t he i nf or mati o n t o t he Safet y e-mail liste d a b o ve (a n d i n Secti o n 1 1. 9 ).
3. M o nit or a n d rec or d t he pr o g ress of t he pre g na nc y  until its o utc o me.  If necessar y  an d a p pr o ve d 
b y  t he s u bject or t heir le gal healt h care re prese ntati ve, c o ntact t he s u bject’s re g ular p h ysicia n 
( ge neral practiti o ner or g y nec ol o gist ) or h os pi[INVESTIGATOR_33717] t o o btai n f urt her details a n d as k f or 
re g ular f oll o w u p i nf or mati o n.
4.  At t he o utc o me of t he pre g na nc y, c o m plete t he Pre g na nc y  Re p ort Part B. F or all t he a d diti o nal 
e val uati o ns, se n d t he f oll o w -u p i nf or mati o n t o t he Safet y e-mail wit hi n [ADDRESS_1103551] ca n n o l o n ger be reac he d (l ost t o f oll o w-u p), d oc u me ntat i o n of 
t he n o n- res p o nse/c o ntact wit h t w o p h o ne calls a n d a letter (certifie d wit h ret ur n recei pt) is 
re q uire d.Title  D o c i d  
[ADDRESS_1103552] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 6 0 of 9 65. If t he pre g na nc y lea ds t o a n a b orti o n ( v ol u ntar y a b orti o n, s p o nta ne o us a b orti o n or t hera pe utic 
a b orti o n), i n uter o deat h or c o n ge nital a n o mal y, f oll o w t he pr oce d ure f or declarati o n of a n 
S A E (see Secti o n 7. 2. 6. 2. 2 ).
7. [ADDRESS_1103553]’s lateral ca nt h us re gi o n, gla bellar 
re gi o n, a n d t he f ull face at baseli ne ( pri or t o treat me nt) a n d at eac h p ost -treat me nt visit.
Eac h In vesti gat or ( or desi g nee) will ta ke p h ot o gra p hs usi n g i de ntical ca mera e q ui p me nt, c o n diti o ns, 
a n d setti n gs. Detaile d i nstr ucti o ns f or p h ot o gra p h y  will be pr o vi de d i n a se parate p h ot o gra p h y 
ma n ual.
7. 3. [ADDRESS_1103554] will be perf or me d pri or t o treat me nt at 
scree ni n g, baseli ne ( pri or t o treat me nt) a n d M o nt h 6 / E T. A ne gati ve pre g na nc y  test is re q uire d f or 
st u d y i ncl usi o n. T he res ult will be d oc u me nte d.
7. [ADDRESS_1103555] u d y V isits
Please refer t o t he Sc he d ule of Assess me nts Ta ble 2 .
A writte n, si g ne d I C F (i ncl usi ve of HI P A A a n d p h ot o c o nse nt) m ust be o btai ne d pri or t o perf or mi n g 
a n y cli nical st u d y-relate d e val uati o ns a n d/ or pr oce d ures. T he s u bject m ust be pr o vi de d wit h a f ull y 
c o m plete d, date d a n d si g ne d c o p y.
8. 1. 1 Scree ni n g/ Visit 1 (-1 4 d a ys t o D a y 0)
T he scree ni n g a n d baseli ne visits m a y  be perf or me d o n t he sa me d a y ; h o we ver, a ma xi m u m of 
[ADDRESS_1103556] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 6 1 of 9 6At t he scree ni n g visit, t he I n vesti gat or or desi g nee will:
1. Re vie w a n d e x plai n t he nat ure of t he st u d y t o t he s u bject , partic ularl y t he pr o hi bite d acti vities 
a n d c o nstrai nts (e. g., restricti o ns f or ot her aest hetic treat me nts a n d t he use of t o pi[INVESTIGATOR_2855] a n d 
s yste mic me dicati o ns, see Secti o n 5. 4. 5 ).
2. O btai n t he si g ne d a n d date d I CF (i ncl usi ve of HI P A A a n d p h ot o c o nse nt); pr o vi de a f ull y 
c o m plete d date d a n d si g ne d c o p y t o t he s u bject.
3. C ollect i nf or mati o n re gar di n g de m o gra p hics (i.e., date of birt h, ge n der, race, et h nicit y, hei g ht, 
a n d wei g ht) , Fitz patric k s ki n t y pe, rele va nt me dical hist or y a n d c o nc urre nt diseases, pre vi o us 
facial treat me nts/ pr oce d ures (i ncl u di n g t o xi n naï ve/ n o n -t o xi n naï ve), pre vi o us me dicati o ns 
a n d pr oce d ures, a n d c o nc o mita nt me dicati o ns a n d pr oce d ures (see Ta ble 2 Sc he d ule of 
A ssess me nts).
4. I nstr uct t he s u bject o n h o w t o c o m plete t he L C L- S L A at  ma xi m u m s mile. 
S u bject t o c o m plete self-assess me nt s usi n g t he 4- p oi nt P h ot o gra p hic Scale s ( LC L -S L A) . L C L 
se verity o f Le vel [ADDRESS_1103557] u d y i ncl usi o n. ( Secti o n 7. 1. 2 a n d A p pe n di x 2 )
5. I nstr uct t he s u bject o n h o w t o c o m plete t he G L -S L A at ma xi m u m fr o w n. S u b ject t o c o m plete 
self-assess me nt usi n g t he Static 4- p oi nt Cate g orical Scale s ( G L-S L A) . M o derate t o se vere G L
(sc ore of 2 or 3 o n t he Static 4- p oi nt Cate g orical Scale )) at ma xi m u m fr o w n, as assesse d b y  
t he s u bject, is re q uire d f or st u d y i ncl usi o n. ( Secti o n 7. 1. 4 )
6. I n vesti gat or t o c o m plete assess me nt of t he s u bject’s bilateral L C L  se verit y at  
 ma xi m u m s mile usi n g t he 4 -p oi nt P h ot o gra p hic Scale s ( L C L-I L A). M o derate t o se vere 
bilaterall y  sy m metrical L C L  (gra de 2 or 3 o n t he L C L- I L A) at ma xi m u m s mile, as assesse d 
b y  t he I n vesti gat or, is re q uire d f or st u dy i ncl usi o n. ( Secti o n 7. 1. 1 a n d A p pe n di x 1 )
7. I n vesti gat or t o c o m plete assess me nt of t he s u bject’s G L se verity at  ma xi m u m fr o w n 
usi n g t he 4 -p oi nt P h ot o gra p hic Scale s ( GL- I L A). M o derate t o se vere G L (gra de 2 or 3 o n t he 
4- p oi nt P h ot o gra p hic Scale) at ma xi m u m fr o w n, as assesse d b y  the i n vesti gat or, is re q uire d 
f or st u d y i ncl usi o n. ( Secti o n 7. 1. 3 a n d A p pe n di x 3 )
8. I n vesti gat or t o p erf or m a foc use d P E . (A p pe n di x 6 ). Rec or d a b n or mal fi n di n gs as me dical 
hist or y . Cli nicall y  si gnifica nt a b n or mal fi n di n gs are e xcl usi o nar y; d oc u me nt as scree n fail a n d 
d o n ot e nr olle d t he s u bject i n t he st u d y .
9. If t he s u bject is a fe male of c hil d beari n g p ote ntial, c ollect uri ne f or U P T a n d c o m plete 
pre g na nc y  test (see la b orat or y ma n ual f or a d diti o nal pr oce d ures). D oc u me nt t he res ult. A 
ne gati ve res ult is re q uire d f or st u d y  i ncl usi o n.
1 0. Rec or d a n y A Es o n t he e C R F. A Es will be c ollecte d starti n g fr o m t he ti me of I nf or me d 
C o nse nt si g nat ure.
1 1. Re vie w t he i ncl usi o n/e xcl usi o n criteria, a n d c o nfir m if s u bject meets st u d y eli gi bilit y
re q uire me nts. 
 If yes, sc he d ule t he baseli ne visit.
 If n o, d oc u me nt t he s u bject as a scree n fail ure.Title  D o c i d  
[ADDRESS_1103558] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103559] i nf or mati o n i nt o t he e C R F; a S I N will be assi g ne d via t he 
e C R F s yste m.
8. 1. 2 B aseli ne / Visit 2 [D a y 0 ]
If t he scree ni n g a n d baseli ne visits are perf or me d as o n sa me d a y , o nl y  p erf or m st u d y assess me nts 
o nce (i.e., A E, c o nc o mita nt t hera pi[INVESTIGATOR_014]/ pr oce d ures, U P T, P E, S L A, I L A, i ncl usi o n/e xcl usi o n re vie w).
A ma xi m u m of 1 4 da y s is all o we d bet wee n t he scree ni n g a n d baseli ne visits. 
At t he b aseli ne visit, t he I n vesti gat or or desi g nee will:
1. As k t he s u bject a b o ut A Es usi n g a n o pe n -e n de d q uesti o n, s uc h as “ Ha ve y o u n otice d a n y 
c ha n ge i n y o ur healt h si nce t he last visit? ” Rec or d all e ve nts, as a p pr o priate .
2. As k t he s u bject a b o ut a n y cha n ges i n his/ her c o nc o mita nt t hera pi[INVESTIGATOR_014]/ pr oce d ures (a d de d, 
re m o ve d or c ha n ge d) si nce t he pre vi o us visit. Rec or d all c ha n ges.
3.
4. I nstr uct t he s u bject o n h o w t o c o m plete t he L C L- S L A at  ma xi m u m s mile. 
S u bject t o c o m plete t he self-assess me nt s usi n g t he 4- p oi nt P h ot o gra p hic Scales ( LC L -S L A).
L C L se verit y of le vel [ADDRESS_1103560] u d y i ncl usi o n. ( Secti o n 7. 1. 2 a n d A p pe n di x 2 )
5. I nstr uct t he s u bject o n h o w t o c o m plete t he G L-S L A at ma xi m u m fr o w n. S u bject t o c o m plete 
t he self-assess me nt usi n g t he Static 4 -p oi nt Cate g orical Scale ( G L-S L A) . M o derate t o se vere 
G L (gra de of 2 or 3 o n t he Static 4- p oi nt Cate g orical Scale ) at ma xi m u m fr o w n, as assesse d 
b y  t he s u bject, is re q uire d f or st u d y i ncl usi o n. ( Secti o n 7. 1. 4 )
6. I n vesti gat or t o c o m plete assess me nt of t he s u bject’s L C L se verity at  
ma xi m u m s mile usi n g t he 4- p oi nt P h ot o gra p hic Scales ( L C L-I L A). M o derat e t o se vere L C L 
(gra de 2 or 3 o n t he 4- p oi nt P h ot o gra p hic Scale) at ma xi m u m s mile, as assesse d b y  the 
I n vesti gat or, is re q uire d f or st u d y i ncl usi o n.
7. I n vesti gat or t o c o m plete assess me nt of t he s u bject’s G L  se verit y at  ma xi m u m fr o w n 
usi n g t he 4- p oi n t P h ot o gra p hic Scale s ( G L-I L A). M o derate t o se vere G L (gra de of 2 or 3 o n 
t he 4- p oi nt P h ot o gra p hic Scale) at ma xi m u m fr o w n, as assesse d b y  the i n vesti gat or, is re q uire d 
f or st u d y i ncl usi o n. ( Secti o n 7. 1. 3 a n d A p pe n di x 3 )
8.
9. O btai n t he s u bject’s vital si g ns ( bl o o d press ure, heart rate, a n d res pi[INVESTIGATOR_1305] y rate). Vital si g ns 
are t o be ta ke n seate d after [ADDRESS_1103561] ( Secti o n 7. 2. 2 ). 
[ADDRESS_1103562] 1 0 mi n utes (Secti o n 7. 2. 3 ). 
[ADDRESS_1103563] (see la b orat or y ma n ual f or a d diti o nal pr oce d ures). D oc u me nt t he res ult. A 
ne gati ve res ult is re q uire d f or st u d y  i ncl usi o n.Title  D o c i d  
[ADDRESS_1103564] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103565] bl o o d sa m ple (c he mistr y an d he mat ol o g y ) f or a nal ys is at t he ce ntral la b orat or y
(Secti o n 7. 2. 4 ).
[ADDRESS_1103566] bl o o d sa m ple f or ne utralizi n g a nti b o d y testi n g ( Secti o n 7. 2. 5 ).
[ADDRESS_1103567] p h ot o gra p hs (refer t o p h ot o ma n ual f or c o m plete i nstr ucti o ns). If t he s u bject is 
weari n g ma ke -u p, i nstr uct t he s u bject t o re m o ve it pri or t o ta ki n g p h ot o gra p hs.
1 5. I n vesti gat or t o perf or m a f oc use d P E. (A p pe n di x 6 ). Cli nicall y  si gnifica nt a b n or mal fi n di n gs 
are e xcl usi o nar y; d oc u me nt as scree n fail a n d d o n ot e nr oll t he s u bject i n t he st u d y.
1 6. Re vie w t he i ncl usi o n/e xcl usi o n criteria, a n d c o nfir m if s u bject meets st u d y eli gi bilit y 
re q uire me nts. 
 If yes, e nr oll/ra n d o mize t he s u bject i n t he cli nical st u d y. Pr ocee d t o ne xt ste ps.
 If n o, d oc u me nt t he s u bject as a scree n fail ure.
1 7. F or all s u bjects, e n ter a p pr o priate data i nt o t he e C R F; t he SI N s h o ul d ha ve bee n assi g ne d via 
t he e C R F sys te m at t he scree ni n g visit
[ADDRESS_1103568]’s kit n u m ber /ra n d o mizati o n assi g n me nt o nce all re q uire d data is 
e ntere d i nt o t he e C R F. T he I n vesti gat or or desi g nee s h o ul d pre pare t he assi g ne d treat me nt 
acc or di n gl y a n d co m plete t he re q uire d d oc u me ntati o n a n d e C R F. ( Secti o n 6. 1. 7 ).
[ADDRESS_1103569]’s treat me nt area s wit h a s uita ble a ntise ptic s ol uti o n.
[ADDRESS_1103570] u d y  ce nter f or 3 0 mi n utes. ( Secti o n 6. 1. 7. 2 )
[ADDRESS_1103571]’s p ost -treat me nt vital si g ns ( bl o o d press ure, heart rate, a n d res pi[INVESTIGATOR_1305] y rate). 
Vital si g ns are t o be ta ke n seate d after 1 0 mi n utes after i njecti o n ( Secti o n 7. 2. 2 ). 
[ADDRESS_1103572] a b o ut A Es usi n g a n o pe n -e n de d q uesti o n. Rec or d all e ve nts, as a p pr o priate, 
o n t he c orres p o n di n g e C R F f or m(s).
[ADDRESS_1103573] -treat me nt c o nc o mita nt t hera pi[INVESTIGATOR_014]/ pr oce d ures .
2 5. Sc he d ule t he ne xt visit ( Da y 7 ± 1 d a y ).
8. 1. 3 D a y 7 / Visit 3 (± 1 d a y)
T he I n vesti gat or or desi g nee will:
1. As k t he s u bject a b o ut A Es usi n g a n o pe n -e n de d q uesti o n, s uc h as “ Ha ve y o u n otice d a n y 
c ha n ge i n y o ur healt h si nce t he last visit? ” Rec or d all e ve nts, as a p pr o priate .
2. As k t he s u bject a b o ut a n y cha n ges i n his/ her c o nc o mita nt t hera pi[INVESTIGATOR_014]/ pr oce d ures (a d de d, 
re m o ve d or c ha n ge d) si nce t he pre vi o us visit. Rec or d all c han ges .
3.  Title  D o c i d  
[ADDRESS_1103574] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103575] t o c o m plete self-assess me nt s usi n g t he 4- p oi nt P h ot o gra p hic Scale ( LC L -S L A) .
( Secti o n 7. 1. 2 a n d A p pe n di x 2 )
5. I nstr uct t he s u bject o n h o w t o c o m plete t he G L -S L A at ma xi m u m fr o w n . S u bject t o c o m plete 
self-assess me nt of G L se verit y at ma xi m u m fr o w n usi n g t he Static 4-p oi nt Cate g orical Scale .
( Secti o n 7. 1. 4 )
6.
7.
8. O btai n t he s u bject’s vital si g ns ( bl o o d press ure, heart rate, a n d res pi[INVESTIGATOR_1305] y rate). Vital si g ns 
are t o be ta ke n seate d after [ADDRESS_1103576] ( Secti o n 7. 2. 2). 
9. Ta ke s u bject p h ot o gra p hs (refer t o p h ot o ma n ual f or c o m plete i nstr ucti o ns). If t he s u bject is 
weari n g ma ke -u p, i nstr uct t he s u bject t o re m o ve it pri or t o ta ki n g p h ot o gra p hs.
[ADDRESS_1103577]’s bilateral L C L  se verit y at  
 ma xi m u m s mile usi n g t he 4- p oi nt P h ot o gra p hic Scale ( L C L-I L A). ( Secti o n 7. 1. 1 a n d 
A p pe n di x 1 )
[ADDRESS_1103578]’s G L se verity at  ma xi m u m fr o w n 
usi n g t he 4 -p oi nt P h ot o gra p hic Scale ( G L-I L A). ( Secti o n 7. 1. 3 a n d A p pe n di x 3 )
1 2. I n vesti gat or t o perf or m a f oc use d P E. (A p pe n di x 6 )
1 3. Sc he d ule t he ne xt visit ( Da y  1 4 ± 3 d a y s).
8. 1. 4 D a y 1 4/ Visit 4 ( ± 3 d a y s)
T he I n vesti gat or or desi g nee will:
1. As k t he s u bject a b o ut A Es usi n g a n o pe n -e n de d q uesti o n, s uc h as “ Ha ve y o u n otice d a n y 
c ha n ge i n y o ur healt h si nce t he last visit? ” Rec or d all e ve nts, as a p pr o priate .
2. As k t he s u bject a b o ut a n y cha n ges i n his/ her c o nc o mita nt t hera pi[INVESTIGATOR_014]/ pr oce d ures (a d de d, 
re m o ve d or c ha n ge d) si nce t he pre vi o us visit. Rec or d all c ha n ges.
3. I nstr uct t he s u bject o n h o w t o c o m plete t he L C L- S L A at  ma xi m u m s mile. 
S u bject t o c o m plete self -assess me nt of bilateral L C L  se verit y t he 4- p oi nt P h ot o gra p hic Scale.
( Secti o n 7. 1. 2 a n d A p pe n di x 2 )
4. I nstr uct t he s u bject o n h o w t o c o m plete t he G L -S L A at ma xi m u m fr o w n . S u bject t o c o m plete 
self-assess me nt of G L se verit y usi n g t he Static 4-p oi nt Cate g orical Scale . ( Secti o n 7. 1. 4 )
5.
6.Title  D o c i d  
[ADDRESS_1103579] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103580]’s vital si g ns ( bl o o d press ure, heart rate, a n d res pi[INVESTIGATOR_1305] y rate). Vital si g ns 
are t o be ta ke n seate d after [ADDRESS_1103581] ( Secti o n 7. 2. 2). 
8. Ta ke s u bject p h ot o gra p hs (refer t o p h ot o ma n ual f or c o m plete i nstr ucti o ns). If t he s u bject is 
weari n g ma ke -u p, i nstr uct t he s u bject t o re m o ve it pri or t o ta ki n g p h ot o gra p hs.
9. I n vesti gat or t o c o m plete assess me nt of t he s u bject’s bilateral L C L  se verit y at  
 ma xi m u m s mile usi n g t he 4- p oi nt P h ot o gra p hic Scale ( L C L-I L A). ( Secti o n 7. 1. 1 a n d 
A p pe n di x 1 )
[ADDRESS_1103582]’s G L se verity at  ma xi m u m fr o w n 
usi n g t he 4 -p oi nt P h ot o gra p hic Scale ( G L-I L A). ( Secti o n 7. 1. 3 a n d A p pe n di x 3 )
1 1. I n vesti gat or t o perf or m a f oc use d P E. (A p pe n di x 6 )
1 2. Sc he d ule t he ne xt visit ( M o nt h 1 ± 5 da y s).
8. 1. 5 M o nt h 1 / Visit 5 ( ± 5 d a y s)
T he I n vesti gat or or desi g nee will:
1. As k t he s u bject a b o ut A Es usi n g a n o pe n -e n de d q uesti o n, s uc h as “ Ha ve y o u n otice d a n y 
c ha n ge i n y o ur healt h si nce t he last visit? ” Rec or d all e ve nts, as a p pr o priate .
2. As k t he s u bject a b o ut a n y cha n ges i n his/ her c o nc o mita nt t hera pi[INVESTIGATOR_014]/ pr oce d ures (a d de d, 
re m o ve d or c ha n ge d) si nce t he pre vi o us visit. Rec or d all c ha n ges.
3. I nstr uct t he s u bject o n h o w t o c o m plete t he L C L -S L A at  ma xi m u m s mile. 
S u bject t o c o m plete self -assess me nt of bilateral L C L  se verity usi n g t he 4- p oi nt P h ot o gra p hic 
Scale. ( Secti o n 7. 1. 2 a n d A p pe n di x 2 )
4. I nstr uct t he s u bject o n h o w t o c o m plete t he G L -S L A at ma xi m u m fr o w n . S u bject t o c o m plete 
self-assess me nt of G L se verit y usi n g t he Static 4-p oi nt Cate g orical Scale . ( Secti o n 7. 1. 4 )
5.
6.
7.
8. O btai n t he s u bject’s vital si g ns ( bl o o d press ure, heart rate, a n d res pi[INVESTIGATOR_1305] y rate). Vital si g ns 
are t o be ta ke n seate d after [ADDRESS_1103583] ( Secti o n 7. 2. 2 ). 
9. O btai n [ADDRESS_1103584] 1 0 mi n utes ( Secti o n 7. 2. 3 ).
[ADDRESS_1103585] bl o o d sa m ple f or ne utralizi n g a nti b o d y testi n g ( Secti o n 7. 2. 5 ).
[ADDRESS_1103586] p h ot o gra p hs (refer t o p h ot o ma n ual f or c o m plete i nstr ucti o ns). If t he s u bject is 
weari n g ma ke -u p, i nstr uct t he s u bject t o re m o ve it pri or t o ta ki n g p h ot o gra p hs.Title  D o c i d  
[ADDRESS_1103587] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103588]’s bilateral L C L  se verit y at  
 ma xi m u m s mile usi n g t he 4- p oi nt P h ot o gra p hic Scale ( L C L-I L A). ( Secti o n 7. 1. 1 a n d 
A p pe n di x 1 )
[ADDRESS_1103589]’s G L se verity at  ma xi m u m fr o w n 
usi n g t he 4 -p oi nt P h ot o gra p hic Scale ( G L-I L A). ( Secti o n 7. 1. 3 a n d A p pe n di x 3 )
1 4. I n vesti gat or t o perf or m a f oc use d P E. (A p pe n di x 6 )
1 5. Sc he d ule t he ne xt visit ( M o nt h 2 ± 5 da y s).
8. 1. 6 M o nt hs 2 - 5/ Visit 6- 9 ( ±5 d a y s)
T he I n vesti gat or or desi g nee will:
1. As k t he s u bject a b o ut A Es usi n g a n o pe n -e n de d q uesti o n, s uc h as “ Ha ve y o u n otice d a n y 
c ha n ge i n y o ur healt h si nce t he last visit? ” Rec or d all e ve nts, as a p pr o priate .
2. As k t he s u bject a b o ut a n y cha n ges i n his/ her c o nc o mita nt t hera pi[INVESTIGATOR_014]/ pr oce d ures (a d de d, 
re m o ve d or c ha n ge d) si nce t he pre vi o us visit. Rec or d all c ha n ges.
3. I nstr uct t he s u bject o n h o w t o c o m plete t he L C L- S L A at  ma xi m u m s mile. 
S u bject t o c o m plete self -assess me nt of bilateral L C L  se verity usi n g t he 4- p oi nt P h ot o gra p hic 
Scale. ( Secti o n 7. 1. 2 a n d A p pe n di x 2 )
4. I nstr uct t he s u bject o n h o w t o c o m plete t he G L -S L A at ma xi m u m fr o w n . S u bject t o c o m plete 
self-assess me nt of G L se verit y usi n g t he Static 4-p oi nt Cate g orical Scale . ( Secti o n 7. 1. 4 )
5.
6.
7.
8. Ta ke s u bject p h ot o gra p hs (refer t o p h ot o ma n ual f or c o m plete i nstr ucti o ns). If t he s u bject is 
weari n g ma ke -u p, i nstr uct t he s u bject t o re m o ve it pri or t o ta ki n g p h ot o gra p hs.
9. I n vesti gat or t o c o m plete assess me nt of t he s u bject’s bilateral L C L  se verit y at  
 ma xi m u m s mile usi n g t he 4- p oi nt P h ot o gra p hic Scale ( L C L-I L A). ( Secti o n 7. 1. 1 a n d 
A p pe n di x 1 )
[ADDRESS_1103590]’s G L se verity at  ma xi m u m fr o w n 
usi n g t he 4 -p oi nt P h ot o gra p hic Scale ( G L-I L A). ( Secti o n 7. 1. 3 a n d A p pe n di x 3 )
1 1. Sc he d ule t he ne xt m o nt hl y visit ( ± 5 da y s).
8. 1. 7 M o nt h 6/ Visit 1 0 or E arl y Ter mi n ati o n visit ( ± 5 d a ys)
At t he Fi nal/ E T, t he I n vesti gat or or desi g nee will:Title  D o c i d  
[ADDRESS_1103591] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103592] a b o ut A Es usi n g a n o pe n -e n de d q uesti o n, s uc h as “ Ha ve y o u n otice d a n y 
c ha n ge i n y o ur healt h si nce t he last visit? ” Rec or d all e ve nts, as a p pr o priate.
2. As k t he s u bject a b o ut a n y cha n ges i n his/ her c o nc o mita nt t hera pi[INVESTIGATOR_014]/ pr oce d ures (a d de d, 
re m o ve d or c ha n ge d) si nce t he pre vi o us visit. Rec or d all c ha n ges.
3. I nstr uct t he s u bject o n h o w t o c o m plete t he L C L- S L A at  ma xi m u m s mile. 
S u bject t o c o m plete self -assess me nt of bilateral L C L  se verity usi n g t he 4- p oi nt P h ot o gra p hic 
Scale. ( Secti o n 7. 1. 2 a n d A p pe n di x 2 )
4. I nstr uct t he s u bject o n h o w t o c o m plete t he G L -S L A at ma xi m u m fr o w n S u bject t o c o m plete 
self-assess me nt of G L se verit y usi n g t he Static 4-p oi nt Cate g orical Scale . ( Secti o n 7. 1. 4 )
5.
6.
7.
8. O btai n t he s u bject’s vital si g ns ( bl o o d press ure, heart rate, a n d res pi[INVESTIGATOR_1305] y rate). Vital si g ns 
are t o be ta ke n seate d after [ADDRESS_1103593] ( Secti o n 7. 2. 2 ). 
9. O btai n [ADDRESS_1103594] 1 0 mi n utes (Secti o n 7. 2. 3 ).
[ADDRESS_1103595] bl o o d sa m ple (c he mistr y  a n d he mat ol o g y) f or a nalys is at t he ce ntral la b orat or y
( Secti o n 7. 2. 4) .
[ADDRESS_1103596] bl o o d sa m ple f or ne utralizi n g a nti b o d y testi n g ( Secti o n 7. 2. 5) .
[ADDRESS_1103597] (see la b orat or y ma n ual f or a d diti o nal pr oce d ures). D oc u me nt t he res ult. 
[ADDRESS_1103598] p h ot o gra p hs (refer t o p h ot o ma n ual f or c o m plete i nstr ucti o ns). If t he s u bject is 
weari n g ma ke -u p, i nstr uct t he s u bject t o re m o ve it pri or t o ta ki n g p h ot o gra p hs.
[ADDRESS_1103599]’s bilateral L C L  se verit y at  
 ma xi m u m s mile usi n g t he 4 -p oi nt P h ot o gra p hic Scale ( L C L-I L A). ( Secti o n 7. 1. 1 a n d 
A p pe n di x 1 )
[ADDRESS_1103600]’s gla bellar li ne se verit y at  
ma xi m u m fr o w n usi n g t he 4- p oi nt P h ot o gra p hic Scale ( G L-I L A). ( Secti o n 7. 1. 3 a n d A p pe n di x 
3 )
1 6. I n vesti gat or t o perf or m a f oc use d P E. (A p pe n di x 6 )
[ADDRESS_1103601] u d y .
8. 2 U nsc he d ule d Visits
W he n necessar y , u nsc he d ule d visits ma y  be c o n d ucte d, i n partic ular if a n A E occ urs a n d nee ds t o 
be assesse d a n d/ or treate d.Title  D o c i d  
[ADDRESS_1103602] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103603] atistic al a n d A n al ytic al P l a ns
A Statistical A nal y sis Pla n ( S A P) will be de vel o pe d as a se parate d oc u me nt. T he S A P will c o ntai n 
a m ore detaile d a n d tec h nical de scri pti o n of s pecific data c o n ve nti o ns, calc ulati o ns a n d of statistical 
pr oce d ures f or e xec uti n g t he a nal ys es t hat are s pecifie d i n t he secti o ns of t he cli nical st u d y pr ot oc ol 
bel o w. T he S A P will be fi nalize d pri or t o data base l oc k .
A se parate S A P f or E U will be create d. T he E U S A P will i ncl u de a res p o n der defi niti o n f or t he 
pri mar y  e n d p oi nt acc or di n g t o t he E U re q uire me nt.
A n y  c ha n ge ma de t o t he fi nalize d S A P will be d oc u me nte d i n t he Cli nical St u d y Re p ort ( C S R).
9. 1. [ADDRESS_1103604] p o p ulati o ns.
9. 1. 2. 1 M o difie d I nte nt -t o-tre at ( mI T T) Effic acy P o p ul ati o n
T he m o difie d I nte nti o n- t o-treat (I T T) p o p ulati o n i ncl u des all s u bjects w h o are ra n d o mize d a n d 
dis pe nse d t he i n vesti gati o nal pr o d uct, a n d will be a nalyz e d acc or di n g t o t he ra n d o mizati o n sc he me; 
s u bjects wit h a p h ot o gra p hic a n d cate g orical scale M o nt h [ADDRESS_1103605] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C CIC CI
C O N FI D E N TI A L
Pa ge 6 9 of 9 69. 1. 2. 2 I nte nt-t o-tre at (I T T) Effic acy P o p ul ati o n
T he I nte nti o n -t o-treat (I T T) p o p ulati o n i ncl u des all s u bjects w h o are ra n d o mize d a n d dis pe nse d t he 
i n vesti gati o nal pr o d uct, a n d will be a nal y ze d acc or di n g t o t he ra n d o mizati o n sc he me. All sec o n dar y 
efficac y  varia bles will be a nal yze d base d o n t he I T T p o p ulati o n , as well as a 
se nsiti vit y a nalys is of t he pri mar y efficac y e n d p oi nt.
9. 1. 2. 3 Per -pr ot oc ol ( P P) Effic acy P o p ul ati o n
T he Per Pr ot oc ol ( P P) p o p ulati o n is a s u bset of t he m I TT s u bjects w h o ha ve n o pr ot oc ol de viati o ns 
t hat are c o nsi dere d t o ha ve a s u bsta ntial i m pact o n t he pri mar y  efficac y outc o me. If t he P P
p o p ulati o n c o ntai ns less t ha n 9 0 % of t he s u bjects i n m I TT, a se nsiti vit y anal ys is of t he pri mar y 
efficac y e n d p oi nt will be perf or me d base d o n t he P P p o p ulati o n.   
9. 1. 2. [ADDRESS_1103606], a n d will be 
a nal yz e d acc or di n g t o as -treate d pri nci ple. All safet y data will be s u m marize d descri pti vel y  base d 
o n t he safe t y p o p ulati o n.
9. 1. 2. 5 I m p ut ati o n of M issi n g D at a
T he O bser ve d Cases ( O C) will be use d f or all safety a nal ys es as well as t he sec o n dar y  
 efficac y a nal yses. T he pri mar y  efficac y a nal ys is will be perf or me d usi n g m ulti ple 
i m p utati o n ( MI) a n d re peate d usi n g baseli ne o bser vati o n carrie d f or war d ( B O C F) f or missi n g 
val ues. If dee me d necessar y , a ny a nal yses ma y be re peate d usi n g O C, B O C F, or MI  as a p pr o priate.
9. 1. 3 D at a P rese nt ati o n a n d G r a p hics
All statistical a nal ys es, i ncl u di n g s u m mar y ta bles a n d d a ta listi n gs, will be perf or me d usi n g t he 
S A S®s yste m ( versi o n 9).
All efficac y, safety a n d baseli ne c haracteristics varia bles will be prese nte d usi n g descri pti ve 
statistics wit hi n eac h treat me nt gr o u p, a n d gra p hs as a p pr o priate. C o nti n u o us data will be 
s u mmarize d usi n g n ( n u m ber of o bser vati o ns), mea n, sta n dar d de viati o n, me dia n, mi ni m u m a n d 
ma xi m u m val ue, w hile cate g orical data will be prese nte d b y n a n d perce nta ges. All data will als o be 
liste d i n s u bject data listi n gs.
S u bject dis p ositi o n, c o m pleti o n a n d disc o nti n uati o n b y  st u d y visit, pr ot oc ol de viati o ns, 
de m o gra p hics a n d baseli ne c haracteristics, me dical hist or y , me dical a n d s ur gical pr oce d ures, pri or 
a n d c o nc o mita nt me dicati o ns, will be s u m marize d b y treat me nt gr o u p.
F or a nal ys is of d urati o n of res p o nse a n d ti me t o o nset of treat me nt res p o nse, Ka pla n -Meier pl ots 
a n d esti mates of t he me dia n e ve nt ti mes will be use d.Title  D o c i d  
[ADDRESS_1103607] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C CI
C CI
C O N FI D E N TI A L
Pa ge 7 0 of 9 69. 1. 3. 1 S u b gr o u p A n alysis
A nal y sis o n t he pr o p orti o n of c o m p osite res p o n ders at M o nt h 1 as meas ure d b y  the I L A a n d t he
S L A at ma xi m u m s mile a n d ma xi m u m fr o w n, se paratel y, will be perf or me d i n t he f oll o wi n g 
s u b gr o u ps:
Ge n der
Baseli ne se verit y sc ore of t he I L A of L C L se verit y at ma xi m u m s mile
Baseli ne se verit y sc ore of t he I L A of G L at ma xi m u m fr o w n
Pre vi o us treat me nt wit h B o N T - A
Fitz patric k s ki n t ype
F or d urati o n of res p o nse, a s u b gr o u p a nal ysis usi n g o nl y s u bjects wit h at least [ADDRESS_1103608] u d y ce nter a n d i n t otal ( b y treat me nt gr o u p a n d 
o verall). De pe n di n g o n t he seri o us ness of t he de viati o n, t he s u bject mi g ht be e xcl u de d fr o m t he P P 
p o p ulati o n, w hic h s hall be d oc u me nte d pri or t o data base l oc k.
9. 1. [ADDRESS_1103609] w h o ac hie ves gra de/le vel [ADDRESS_1103610] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103611] t he alter nati ve h y p ot hesis 
t hat t here is a relati o ns hi p bet wee n treat me nt a n d res p o n der rate (f or eac h of t he f o ur c o m paris o ns). 
T he res p o n der rates of Q M [ADDRESS_1103612] (stratifie d b y  ce nter) at 5 % si g nifica nce le vel ( 2-si de d). De pe n di n g of t he n u m ber of ce nters, 
p o oli n g of ce nters mi g ht be nee de d. T he gr o u p treate d i n o ne r h yt i d area (L C L  or G L) al o ne a n d t he 
gr o u p wit h c o nc urre nt L C L  an d G L treat me nt will be a nal yz e d se parately. T o c o ntr ol t he t ype I err or 
rate a m o n g t he [ADDRESS_1103613] me nt t o t he le vel of si g nifica nce. T he c o m paris o ns will be d o ne i n t he f oll o wi n g 
or der:
1. G L  al o ne gr o u p vs place b o o n t he G L scale
2. G L  + L C L gr o u p vs place b o o n t he G L scale
3. L C L al o ne gr o u p vs place b o o n t he L C L  scale
4. G L  + L C L gr o u p vs place b o o n t he LC L  scale
T he a nal ys is of t he pri mar y efficac y en d p oi nt will be base d o n t he mI T T p o p ulati o n.  A se nsiti vit y 
a nal ys is of t he pri mar y  efficac y e n d p oi nt will be perf or me d usi n g t he I T T p o p ulati o n.
F or re gistrati o n of t he pr o d uct i n t he E U, a differe nt defi niti o n of t he pri mar y  efficac y en d p oi nts will 
be use d.   
All ot her e n d p oi nts will be a nal yze d descri pti vel y . F or efficac y, perce nta ges of s u bjects o ver ti me 
will be prese nte d i n gra p hs. D urati o n of treat me nt effect a n d ti me t o o nset will be a nal yze d wit h 
Ka pla n -Meier met h o ds.
9. 2 S a m ple S ize D eter mi n ati o n
T he sa m ple size is deter mi ne d b y  the n u m ber of s u bjects e x p ose d t o Q M 1 1 1 4 -D P i n t he L C L a n d 
G L , a n d a m o u nt of l o n g-ter m safety data.
F urt her, d ue t o t he p u blic healt h e mer ge nc y  relate d t o t he C O VID- 1 9 pa n de mic d uri n g 2 0 2 0 , ste ps 
ha ve bee n ta ke n t o e ns ure patie nt a n d practiti o ner safety i n ali g n me nt w it h F D A G ui da nce date d 
Ma y  11, 2 0 2 0 ( Gui d a nce o n C o n d uct of Cli nic al Tri als of Me dic al Pr o d ucts d uri n g C O VI D -1 9 
P u blic He alt h E mer ge ncy ). M ost n ota bl y, i n part ners hi p wit h cli nical sites a n d t he I R B, o pti o nal 
re m ote assess me nt pr oce d ures f or efficac y an d s afet y en d p oi nts has bee n i m ple me nte d t o e ns ure 
safety a n d res pect l ocalize d a n d electi ve restricti o ns. T her ef ore, t he sa m ple size has bee n i ncrease d 
d uri n g t he c o n d uct of t he st u d y t o e ns ure a s ufficie nt n u m ber of s u bjects i n t he mI T T p o p ulati o n 
use d i n t he assess me nt of t he pri mar y efficac y e n d p oi nt.
9. 2. [ADDRESS_1103614] u d y was i nitiall y pla n ne d t o e nr oll a p pr o xi matel y 35 0 s u bjects w h o will be treate d wit h eit her:
6 0 u nits Q M 1 1 1 4 -D P ( [ADDRESS_1103615] b o i n t he G L, 1 0 0 s u bjects),
5 0 u nits Q M 1 1 1 4 -D P ( [ADDRESS_1103616] b o i n t he L C L, 1 0 0 s u bjects),Title  D o c i d  
[ADDRESS_1103617] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 7 2 of 9 61 1 0 u nits Q M 1 1 1 4 -D P ( 6 0 u nits i n t he L C L  a n d 5 0 u nits i n t he G L, 1 0 0 s u bjects), or 
Place b o i n b ot h t he L C L  a n d G L ( 5 0 s u bjects).
D uri n g t he st u d y the sa m ple size was i ncrease d d ue t o t he p u blic healt h e mer ge nc y relate d t o t he 
C O VI D - [ADDRESS_1103618] u d y 
is pla n ne d t o e nr oll a p pr o xi matel y 4 1 3 s u bjects w h o will be treate d wit h eit her:
6 0 u nits Q M 1 1 1 4 -D P ( [ADDRESS_1103619] b o i n t he G L, 1 1 8 s u bjects),
5 0 u nits Q M 1 1 1 4 -D P ( [ADDRESS_1103620] b o i n t he L C L, 1 1 8 s u bjects),
1 1 0 u nits Q M 1 1 1 4 -D P ( 6 0 u nits i n t he L C L  a n d 5 0 u nits i n t he G L, 1 1 8 s u bjects), or 
Place b o i n b ot h t he L C L  a n d G L ( 5 9 s u bjects).
N o pre vi o us data o n c o m p osite res p o n der rates, wit h t he sa me defi niti o n of c o m p osite res p o n der as 
i n t he c urre nt st u d y, is a vaila ble f or s u bjects treate d wit h Q M [ADDRESS_1103621] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103622] u d y is pla n ne d t o i ncl u de a p pr o xi matel y 35 0 s u bjects i n t he mI T T p o p ulati o n : [ADDRESS_1103623] u d y.
1 0. T R AI NI N G / M O NI T O RI N G / D A T A M A N A G E M E N T / Q U A LI T Y A S S U R A N C E
[ADDRESS_1103624] u d y pr ot oc ol, I C H -G C P g ui deli nes, a n d a p plica ble S O Ps.  
T he I n vesti gat or will all o w t he C R O/ S p o ns or’s re prese ntati ves, t o h a ve direct access t o all cli nical 
st u d y rec or ds, C R Fs, c orres p o n di n g s u bject me dical rec or ds, st u d y pr o d uct (s) dis pe nsi n g rec or ds, 
a n d a n y ot her d oc u me nts c o nsi dere d s o urce d oc u me ntati o n.  Ad diti o nall y , t he C R O/ S p o ns or 
re prese ntati ve is t o ha ve access t o t he st u d y pr o d uct st ora ge area a n d cli nical st u d y facilities.
T he I n vesti gat or als o a grees t o assist t he re p rese ntati ve if re q uire d.
1 0. 3 D at a M a n a ge me nt
Data ma na ge me nt base d o n G C P refers t o t he acti vities defi ne d t o ac hie ve safe r o uti nes t o e nter 
cli nical data i nf or mati o n i nt o a data base, efficie ntl y an d a v oi di n g err ors. T he data ma na ge me nt 
r o uti ne i ncl u des pr oce d ures f or data base set- u p a n d ma na ge me nt, data e ntr y an d verificati o n, data 
vali dati o n, a n d d oc u me ntati o n of t he perf or me d acti vities i ncl u di n g i nf or mati o n of discre pa ncies i n 
t he pr ocess. T he data ma na ge me nt pr ocess will be descri be d i n detail i n t he data ma na ge me nt pla n 
( D M P).Title  D o c i d  
[ADDRESS_1103625] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103626] u gs a n d e ve nts will be c o de d i n acc o r da nce wit h W orl d Healt h Or ga nizati o n ( W H O) Dr u g 
a n d me dical dicti o nar y  for re g ulat or y acti vities ( Me d D R A) dicti o naries as s pecifie d i n t he D M P. 
Safet y  data ( S A E a n d if a p plica ble A E of s pecial i nterest) i n t he cli nical data base will be rec o ncile d 
a gai nst t he data i n t he safet y data base.
W he n all eff orts ha ve bee n ma de t o e ns ure t hat t he data rec or de d i n t he e C R Fs a n d e ntere d i n t he 
data base is as c orrect a n d c o m plete as p ossi ble, t he cli nical data base will be l oc ke d. St u d y  data will 
be tra nsferre d t o S A S d atasets, w hic h t hereafter will be write -pr otecte d. Statistical a nal ys es will be 
ge nerate d i n S A S usi n g data fr o m t he l oc ke d datasets.
1 0. 4 Q u alit y Ass ur a nce/ A u dit /I ns pecti o n
T he cli nical st u d y is c o n d ucte d u n der t he s p o ns ors hi p of t he S p o ns or i n c o m plia nce wit h t he 
a p plica ble i nter nati o nal a n d l ocal re g ulat or y  re q uire me nts as well as a p plica ble I C H g ui deli nes a n d 
i n acc or da nce wit h t he S O Ps f or cli nical st u d y c o n d uct a n d m o nit ori n g fr o m t he S p o ns or a n d/ or t he 
C o ntract Researc h Or ga nizati o n ( C R O).
A u dits of cli nical st u d y ce nters m a y  be c o n d ucte d b y  the S p o ns or/ C R O re prese ntati ves, a n d 
i ns pecti o n ma y  be perf or me d b y  Re g ulat or y Aut h orit y  ins pect orates or I RBs/I E Cs bef ore, d uri n g, 
or after t he cli nical st u d y.  
T he I n vesti gat or will all o w a n d assist t he C R O/ S p o ns or’ s re prese ntati ves, I RBs/I E Cs a n d a n y 
re g ulat or y a ge nc y t o ha ve direct access t o all re q ueste d cli nical st u d y-relate d rec or ds.
F or t he a u dits perf or me d b y, or o n be half of, t he S p o ns or a u dit ors, a u dit certificate(s) will be 
pr o vi de d b y Q ualit y Ass ura nce.
[ADDRESS_1103627]/ A me n d me nts
[ADDRESS_1103628] u d y pr ot oc ol or i m ple me nt a n y c ha n ges wit h o ut writte n a p pr o val fr om 
t he S p o ns or a n d pri or re vie w a n d d oc u me nte d a p pr o val/fa v ora ble o pi [INVESTIGATOR_9384] o n fr o m t he I RB/I E C of a 
pr ot oc ol a me n d me nt.
C ha n ges t hat i n v ol ve o nl y  lo gistical or a d mi nistrati ve c ha n ges t o t he cli nical st u d y pr ot oc ol are 
a ut h orize d.  The I n vesti gat or s h o ul d d oc u me nt a n d e x plai n a n y de viati o n fr o m t he cli nical st u d y
pr ot oc ol.Title  D o c i d  
[ADDRESS_1103629] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103630] u d y pr ot oc ol at a n y ti me f or et hical, me dical, or scie ntific 
reas o ns. A ny a me n d me nts will be ha n dle d acc or di n g t o a p plica ble l ocal re g ulati o ns.
T he S p o ns or d oes n ot ha ve t o n otif y  no n- s u bsta ntial a me n d me nts t o t he c o m pete nt a ut h orities or t he 
Et hics C o m mittees. H o we ver, n o n- s u bsta ntial a me n d me nts s h o ul d be rec or de d a n d detaile d i n 
s u bse q ue nt s u b missi o ns e. g., i n t he s u bse q ue nt n otificati o n of a s ubsta ntial a me n d me nt.
1 1. E T HI C S A N D G E N E R A L C LI NI C A L S T U D Y C O N D U C T C O N SI D E R A TI O N S
1 1. 1 I n de pe n de nt Et hics C o m mittee (I E C) or I nstit uti o n al Re vie w B o ar d (I R B)
T his cli nical st u d y pr ot oc ol a n d all a p plica ble a me n d me nts will be re vie we d a n d a p pr o ve d b y  the 
a p pr o priate I E Cs/IR Bs.
[ADDRESS_1103631] u d y will be c o n d ucte d i n acc or da nce wit h t he pr ot oc ol , t he H E L SI N KI declarati o n 
( 1 9 6 4) a n d s u bse q ue nt a me n d me nts, a n d t he I C H G C P, a n d i n c o m plia nce wit h a p plica ble 
re g ulat or y re q uire me nts. 
[ADDRESS_1103632] u d y i n acc or da nce wit h G C Ps g ui deli nes, fe deral re g ulati o ns, HI P A A , a n d g ui deli nes a n d i n 
acc or da nce wit h l ocal re q uire me nts.  
T he I C F (i ncl usi ve of HI P P A a n d p h ot o c o nse nt ), a p pr o ve d b y a n I R B/I E C, will be f ully e x plai ne d 
t o t he s u bject.  T he s u bject m ust a gree t o p h ot o c o nse nt i n or der t o partici pate i n t he cli nical stu d y . 
Pri or t o e nr ol lme nt i nt o t he cli nical st u d y, t he s u bject a n d t he PI [INVESTIGATOR_1311] g nee m ust si g n a n d date t he 
c o nse nt f or m(s).  The I nvesti gat or is res p o nsi ble f or mai ntai ni n g eac h s u bject’s c o nse nt f or m(s) i n 
t he I nvesti gat or’s site file a n d pr o vi di n g eac h s u bject wit h a c o p y of t he si g ne d a n d date d c o nse nt 
f or m(s).
[ADDRESS_1103633] u d y  i n v ol ves t he gat heri n g a n d pr ocessi n g of Pers o nal Data as s pecifie d i n 
t he Re g ulati o n ( E U) 2 0 1 6/ [ADDRESS_1103634] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103635] of 1 9 9 6 ( HIP A A), as pr o vi de d at C F R § 5 1 2( b)(iii), a n d t he st u d y su bject s h o ul d be ma de a ware 
of t his e xce pti o n i n t he i nf or me d c o nse nt. T he S p o ns or s hall, t o t he e xte nt feasi ble, pr otect st u d y 
s u bject i de ntifier i nf or mati o n.
T he I nstit uti o n a n d Pri nci pal I n vesti gat or are j oi ntl y res p o nsi ble f or o btai ni n g t he a p pr o priate 
i nf or me d c o nse nt of eac h s u bject f or t he pr ocessi n g of Pers o nal Data re q uire d i n or der t o c o m plete 
t he st u d y. S uc h c o nse nt s hall i ncl u de t he c o nse nt t o t he tra nsfer of Pers o nal Data t o g o ver n me nt 
a ut h orities l ocate d i n c o u ntries o utsi de t he U S. 
T he I nstit uti o n a n d Pri nci pal I nvesti gat or are j oi ntl y res p o nsi ble f or pr o vi di n g s ufficie nt i nf or mati o n 
t o all s u bjects t o e na ble t he m t o gi ve t heir i nf or me d c o nse nt n ot o n l y to t he partici pati o n i n t he st u d y, 
b ut als o t o t he pr ocessi n g of Pers o nal Data. S uc h i nf or mati o n i ncl u des i nf or mati o n re gar di n g t he 
p ur p oses of t he pr ocessi n g, t he le n gt h of ti me d uri n g w hic h Pers o nal Data will be st ore d, t he ri g ht 
of access t o st ore d P ers o nal Data a n d t he ri g ht t o c orrecti o n or p ur gi n g of i nc orrect or o bs olete 
Pers o nal Data. A s u bject ma y als o wit h dra w his or her c o nse nt at a n y ti me d uri n g or after t he st u d y .
A s u bject w h o wit h dra ws his or her c o nse nt t o t he pr ocessi n g of Pers o nal Data m ust be c o nsi dere d 
t o ha ve wit h dra w n fr o m t he st u d y but t he data c ollecte d u ntil t he c o nse nt was wit h dra w n m a y  be 
use d i n t he statistical a nal y ses or t o c o m pl y  wit h le gal or a d mi nistrati ve re q uire me nts.
All c ollecti o n, pr ocessi n g a n d a nal yses of pr otecte d healt h i nf or mati o n, pers o nal data or si milar will 
be c o n d ucte d i n c o m plia nce wit h a p plica ble l ocal, nati o nal a n d i nter nati o nal r ules, re g ulati o ns a n d 
g ui deli nes.
[ADDRESS_1103636] ual a gree me nt will be si g ne d bet wee n t he C R O/ S p o ns or a n d eac h I n vesti gat or/I nstit uti o n.  
T his d oc u me nt will c o ntai n s u p ple me ntar y inf or mati o n, i ncl u di n g fi na ncial ter ms, c o nfi de ntialit y, 
t he cli nical st u d y sc he d ule, t hir d party res p o nsi bilit y, a n d p u blicati o n ri g hts.
[ADDRESS_1103637]’s s o urce d oc u me nts a n d i n t he eC R Fs pr o vi de d b y t he S p o ns or.  All data 
s h o ul d be rec or de d in t he eC R Fs c o m pletel y a n d pr o m ptl y.Title  D o c i d  
[ADDRESS_1103638] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103639] kee p acc urate se parate rec or ds ( ot her t ha n t he eC R Fs) of all s u bject visits, 
bei n g s ure t o i ncl u de all perti ne nt cli nical st u d y-relate d i nf or mati o n.  A state me nt s h o ul d be ma de 
i n dicati n g t hat t he s u bjects ha ve bee n i ncl u de d i n t his cli nical st u d y a n d ha ve pr o vi de d si g ne d writte n 
I nf or me d C o nse nt.  All A Es m ust be t h or o u g hly d oc u me nte d.
Res ults of a n y dia g n ostic tests c o n d ucte d d uri n g t he cli nical st u d y s h o ul d als o be i ncl u de d i n t he 
s o urce d oc u me ntati o n.  
[ADDRESS_1103640] u d y will be mai ntai ne d 
sec urely i n S p o ns or/ C R O/I n vesti gat or/I nstit uti o n arc hi ves f or t he le gall y re q uire d d urati o n f or 
arc hi vi n g.
T he I nvesti gat or/I nstit uti o n s h o ul d mai ntai n t he esse ntial cli nical st u d y d oc u me nts as s pecifie d i n 
Secti o n 8 of I C H -G C P, a n d acc or di n g t o t he a p plica ble re g ulat or y  re q uire me nts.
T he I nvesti gat or/I nstit uti o n s h o ul d ta ke meas ures t o pre ve nt acci de ntal or pre mat ure destr ucti o n of 
t hese d oc u me nts.
If t he Pri nci pal I n vesti gat or retires, rel ocates, or wit h dra ws fr o m t he res p o nsi bilit y of kee pi n g t he 
cli nical st u d y rec or ds f or a n y ot her reas o ns, c ust o d y m ust be transferre d t o a pers o n w h o will acce pt 
t he res p o nsi bilit y.  The S p o ns or/ C R O m ust be n otifie d i n writi n g of t he na me a n d a d dress of t he 
ne w c ust o dia n.
1 1. 7 I ns ur a nce
A certificate attesti n g T hir d Part y  c o vera ge of C R O/ S p o ns or will be pr o vi de d u p o n re q uest.
1 1. 8 P u blic ati o n P olic y
T he I nstit uti o n/ PI’s a n d t he S p o ns or’s o bli gati o ns re gar di n g i ntellect ual pr o pert y ri g hts, 
c o nfi de ntialit y, a n d p u blicati o ns are descri be d i n detail i n t he C T A.
T he ai m is t o s u b mit t he res ults of t his st u d y for p u blicati o n i n a p u blic d ata base (e. g., 
w w w. Cli nical Trials. g o v) a n d t o a me dical j o ur nal f or p u blicati o n of t he res ults. E ver y o ne w h o is t o 
be liste d as a n a ut h or of t he res ults of t his m ultice nter st u d y shall ha ve ma de a s u bsta ntial, direct, 
i ntellect ual c o ntri b uti o n t o t he w or k. A ut h ors hi p will be base d o n ( 1) s u bsta ntial c o ntri b uti o ns t o t he 
c o nce pti o n or desi g n of t he w or k; or t he ac q uisiti o n, a nal ys is, or i nter pretati o n of data f or t he w or k; 
a n d ( 2) drafti n g t he w or k or re visi n g it criticall y f or i m p orta nt i ntellect ual c o nte nt ; a n d ( 3) fi nal 
a p pr o val of t he versi o n t o be p u blis he d; a n d ( 4) a gree me nt t o be acc o u nta ble f or all as pects of t he 
w or k i n e ns uri n g t hat q uesti o ns relate d t o t he acc urac y or i nte grit y of a n y part of t he w or k are Title  D o c i d  
[ADDRESS_1103641] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103642] all be met i n or der t o be 
desi g nate d as a ut h or. T h ose w h o d o n ot meet all f o ur criteria will be ac k n o wle d ge d. A m o n g t he 
a ut h ors t hat f ulfil t he a b o ve-me nti o ne d criteria, o ne a ut h or will be a p p oi nte d b y t he S p o ns or t o ta ke 
pri m ar y res p o nsi bilit y f or t he o verall w or k as pri mar y a ut h or.
                                                
aDefi ni n g t he r ole of a ut h ors a n d c o ntri b ut ors, c o m pi[INVESTIGATOR_5829] d b y t he I nter nati o nal C o m mittee of Me dical J o ur nal E dit ors 
(I C MJ E) ( htt p:// w w w.ic mje. or g).Title  D o c i d  
[ADDRESS_1103643] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103644]:
Me dical M o nit or:
Safet y  e-mail f or S A E,
Pre g na nc y Re p orti n g , a n d 
P Q C :E- mail: 
C R O:Title  D o c i d  
[ADDRESS_1103645] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103646] 
l ocalize d a n d electi ve restricti o ns were i m ple me nte d d ue t o C O VI D - 1 9 pa n de mic. T heref ore, the 
m o difie d I nte nti o n-t o-treat ( mI TT) efficac y p o p ulati o n is a d de d t o t he statistical a nal yses f or 
pri mar y  efficac y an al y sis. F urt her, the sa m ples size is i ncrease d t o e ns ure e n o u g h s u bjects i n t he 
mI T T p o p ulati o n. T h ese acti o ns affect se veral secti o ns of t he Pr ot oc ol as s u m marize d bel o w .
Secti o n i n t he cli nic al 
st u d y pr ot oc olR ati o n al f or c h a n ges Descri pti o n of c h a n ges
S y n o psis ; Ta ble 1 ; 
Fi g ure 1; 
Secti o n 3, O verall cli nical 
st u d y descri pti o n;
Secti o n 5. 1 , N u m ber of 
s u bjectsD ue t o C O VI D - 1 9 pa n de mic
acti o ns .
The sa m ples size is i ncrease d to 
e ns ure e n o u g h s u bjects i n t he 
mI T T p o p ulati o n .U p date d n u m ber of s u bjects.
A p pr o xi matel y 4 5 4 s u bjects will be 
scree ne d i n or der t o get 4 1 3 s u bjects 
e nr olle d i n a 2: 2: 2: 1 rati o t o:
•  60 u nits Q M 1 1 1 4 -D P ( [ADDRESS_1103647] b o i n t he G L, 1 1 8 
s u bjects),
•  50 u nits Q M 1 1 1 4 -D P ( [ADDRESS_1103648] b o i n t he L C L, 1 1 8 
s u bjects),
•  11 0 u nits Q M 1 1 1 4 -D P ( 6 0 u nits i n t he 
L C L a n d 5 0 u nits i n t he G L, 1 1 8 
s u bjects), or 
•  Place b o i n b ot h t he L C L a n d G L ( 5 9 
s u bjects).
Secti o n 9. 1. 1, Data 
Tra nsf or mati o nsClarificati o n  
 
Secti o n 9. 1. 2. 1, M o difie d 
I nte nt-t o-treat ( mI T T) 
Efficac y P o p ulati o n ;
List of a b bre viati o ns a n d 
defi niti o ns of ter msD ue t o C O VI D - 1 9 pa n de mic
acti o ns.
T he mI T T efficac y p o p ulati o n 
will be use d f or assess me nt of t he 
pri mar y efficac y e n d p oi nt . 
S u bjects wit h a p h ot o gra p hic a n d 
cate g orical scale M o nt h 1 
assess me nt via a re m ote visit will 
be e xcl u de d fr o m t he mI T T .M o difie d I nte nt-t o-treat ( mI T T) Efficac y 
P o p ulati o n a d de d ( primar y efficac y 
a nal ysis) .
Secti o n 9. 1. 2. 2, I nte nt t o 
treat (I T T) Efficac y 
P o p ulati o nD ue t o C O VI D - [ADDRESS_1103649] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103650] u d y pr ot oc olR ati o n al f or c h a n ges Descri pti o n of c h a n ges
Secti o n 9. 1. 2. 3, Per-
pr ot oc ol ( P P) Efficac y 
P o p ulati o nClarificati o n d ue t o C O VI D -1 9 
pa n de mic acti o ns.C ha n ge d fr o m “I T T” t o “ mI T T”
Secti o n 9. 1. 2. 5, 
I m p utati o n   of Missi n g 
DataD ue t o C O VI D - [ADDRESS_1103651] o p -
o uts/ missi n g data at M o nt h 1
visit.Pri mar y i m p utati o n c ha n ge d t o “MI ”
i nstea d of “B O C F ”.
Secti o n 9. 1. 5, I nfere ntial 
Statistical A nal ysesClarificati o n d ue t o C O VI D -1 9 
pa n de mic acti o ns.A d de d: 
“ T he a nal ysis of t he pri mar y efficac y 
e n d p oi nt will be base d o n t he mI T T 
p o p ulati o n.  A se nsiti vit y a nal ysis of t he 
pri mar y efficac y e n d p oi nt will be 
perf or me d usi n g t he I T T p o p ulati o n.”
Secti o n 9. 2, Sa m ple Size 
Deter mi nati o nCla rificati o n d ue t o C O VI D -[ADDRESS_1103652] u d y 
a d de d.
“ T he sa m ple size is deter mi ne d b y t he 
n u m ber of s u bjects e x p ose d t o Q M 1 1 1 4 -
D P i n t he L C L a n d G L, a n d a m o u nt of 
l o n g-ter m safet y data.” was m o ve d fr o m 
S ecti o n 9. 2. [ADDRESS_1103653] orical DataClarificati o n d ue t o C O VI D -1 9 
pa n de mic acti o ns.B ot h t he i nitiall y pla n ne d a n d t he 
i ncrease d sa m ple size i ncl u de d. 
Secti o n 9. 2. 3, Sa m ple 
Size Calc ulati o nClarificati o n d ue t o C O VI D -1 9 
pa n de mic acti o ns.A d de d : “ … i n t he mI T T p o p ulati o n
… …”
Secti o n 1 2: Secti o n 1 2. 1 Pr ot oc ol A me n d me nt A d de d Secti o n: S u m mar y of C ha n ges 
Pr ot oc ol versi o n 3. [ADDRESS_1103654] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 8 2 of 9 61 3. LI T E R A T U R E R E F E R E N C E LI S T
1.I C H E 6: I nter nati o nal C o nfere nce o n Har m o nisati o n Tri partite G ui deli ne:  G ui deli ne f or G o o d 
Cli nical Practice. [ADDRESS_1103655] hetics C o nse ns us ( 2 0 1 6). 
" Gl o bal Aest hetics C o nse ns us: B ot uli n u m T o xi n T ype A --E vi de nce -Base d Re vie w, E mer gi n g 
C o nce pts, a n d C o nse ns us Rec o m me n dati o ns f or Aest hetic Use, I ncl u di n g U p dates o n 
C o m plicati o ns." Plast Rec o nstr S ur g 1 3 7( 3): 5 1 8e -5 2 9e.
3. A wa n, K. H. ( 2 0 1 7). " T he t hera pe utic usa ge of b ot uli n u m t o xi n ( B ot o x) i n n o n -c os metic hea d 
a n d nec k c o n diti o ns - A n e vi de nce base d re vie w." Sa u di P har m J 2 5( 1): 1 8 - 2 4.
4. Sc ott A B. B ot uli n u m t o xi n i njecti o n i nt o e xtra oc ular m uscles as a n alter nati ve t o
stra bis m us s ur ger y. Op ht hal m ol o g y .  1 9 8 0; 8 7: 1 0 4 4- 9.
5. M o n heit, G. D. a n d A. Pic kett ( 2 0 1 7). " A b o b ot uli n u mt o xi n A: A [ADDRESS_1103656] or y ." Aest het 
S ur g J 3 7(s u p pl _ 1): S 4 -s 1 1.
6. Dressler, D., S. V o gt a n d F. Sa beri ( 2 0 1 6). " Der Off- La bel Use a m Beis pi[INVESTIGATOR_799853] 
B ot uli n u mt o xi n -T hera pie." Kli nisc he Ne ur o p h ys i ol o gie 4 7( 0 2): 8 7- 9 1.
7. L u p o, M. P. ( 2 0 1 6). " T o x O utsi de t he B o x: Off -La bel Aest hetic Uses of B ot uli n u m T o xi n." J 
Dr u gs Der mat ol 1 5( 9): 1 1 5 1 - 1 1 5 7.
8. Ca m pa nati, A., E. Marti na, K. Gi uli o d ori, V. C o nsales, I. B o b yr a n d A. Offi da ni ( 2 0 1 7). 
" B ot uli n u m T o xi n Off-La bel Use i n Der mat ol o g y: A Re vie w." S ki n A p pe n da ge Dis or d 3( 1): 
3 9- 5 6.
9. Carr ut hers, J. a n d A. Carr ut hers ( 2 0 0 7). " T he e v ol uti o n of b ot uli n u m ne ur ot o xi n t y pe A f or 
c os metic a p plicati o ns." J C os met L aser T her 9( 3): [ADDRESS_1103657] u d y  ( 2 0 0 7). " Re peate d b ot uli n u m t o xi n A i njecti o ns f or t he treat me nt of li nes 
i n t he u p per face: a retr os pecti ve st u d y of 4, 1 0 3 treat me nts i n 9 4 5 patie nts." Der mat ol S urg 
3 3( 1 S pec N o.): S 1 8 - 2 5.
1 1. Pi[INVESTIGATOR_799854], M., O. R ossett o, R. Ele o pra a n d C. M o ntec ucc o ( 2 0 1 7). " B ot uli n u m Ne ur ot o xi ns: 
Bi ol o g y , P har mac ol o g y, a n d T o xic ol o g y." P har mac ol Re v 6 9( 2): 2 0 0- 2 3 5.
1 2. I n vesti gat ors Br oc h ure Q M 1 1 1 4 -D P ( B ot uli n u m Ne ur ot o xi n T y pe A) U p per Fa cial Wri n kles, 
e diti o n 5
1 3. P usic A L , Klasse n A F, Sc ott A M, Ca n o SJ. De vel o p me nt a n d ps yc h o metric e val uati o n of t he 
F A C E - Q satisfacti o n wit h a p peara nce scale: a ne w patie nt-re p orte d o utc o me i nstr u me nt f or 
facial aest hetic patie nts. Cli n Plast S ur g 2 0 1 3; 4 0( 2): 2 4 9- 2 6 0
1 4. Klasse n A F, Ca n o SJ, Sc ott A M, P usic A L . Meas uri n g o utc o mes t hat matter t o face-lift 
patie nts: de vel o p me nt a n d vali dati o n of F A C E - Q a p peara nce a p praisal scales a n d a d verse 
affects c hec klist f or t he l o wer face a n d nec k. Plast Rec o nstr S ur g 2 0 1 4; 1 3 3( 1): 2 1 - 3 0
1 5. I C H E 2 A: I nter nati o nal C o nfere nce o n Har m o nisati o n Tri partite G ui deli ne:  Cli nical 
Safet y Data Ma na ge me nt: Defi niti o ns a n d Sta n dar ds f or E x pe dite d Re p orti n g. 1 9 9 4
1 6. F D A G ui da nce for I n d ustr y. U p per Facial Li nes: de vel o pi n g b ot uli n u m t o xi n dr u g 
pr o d u cts ( draft), [ADDRESS_1103658] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103659] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103660] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103661] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103662] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103663] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103664] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103665] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103666] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103667] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103668] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C CI
C O N FI D E N TI A L
Pa ge 9 3 of 9 6A p pe n di x 6 F oc use d P h ysic al E x a mi n ati o n F or m E x a m ple
N ot d o n e       Pr o vi d e d et ails: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Ge ner al He alt h Assess me nt
C o m plete at Scree ni n g, B aseli ne ( pri or t o tre at m e nt), D a y 7, D a y 1 4, M o nt hs 1 a n d 6/ E T
Q uesti o n t he s u bject a b o ut t heir ge neral healt h ( ge neral well bei n g/ b o dil y f u ncti o ns, e. g., ar ms, le gs, st o mac h/ bla d der/ 
b o w el, als o refer t o t he list of A d verse E ve nts P ote ntiall y S u g gesti ve of  Dista nt S prea d of T o xi n (A p pe n di x 7) . 
A b n or m alities n ote d pre -i njecti o n s h o ul d be rec or de d as me dical hist or y a n d I n vesti gat or s h o ul d c o nfir m if a n y 
a b n or malities affect s u bject eli gi bilit y. A b n or malities n ote d p ost -i njecti o n sh o ul d be d oc u me nte d as A Es.
Ne xt, pr ocee d t o t he F oc use d P h ysical E xa mi nati o n ( Part 1 a n d 2) as i n dicate d bel o w .
P art 1:
C o m plete at Scree ni n g, B aseli ne ( pri or t o tre at m e nt), D a y 7, D a y 1 4, M o nt hs 1 a n d 6/ E T
Please perf or m a tar gete d e xa mi nati o n of t he face, hea d, a n d nec k rec or di n g a b n or malities. 
P art 1 E x a m i n ati o n N o r m al A b n or m al * ( pr o vi de det ails)
E y eli d p ositi o n
E y e br o w p ositi o n 
Visi o n a b n or malities ( n ot 
refracti ve err ors)
T hr oat f u ncti o n (e. g., 
s wall o wi n g/ dri n k water)
A bilit y t o tal k a n d c he w
A bilit y t o stic k o ut a n d m o ve 
t o n g ue
A bilit y t o lift s h o ul ders 
* A b n or m al fi n di n gs at t he scree ni n g a n d b aseli ne visit, n ote d pre- i njecti o n, s h o ul d be rec or de d as me dic al 
hist or y a n d t he I n vesti g at or s h o ul d c o nfir m if a n y a b n or m alities affect s u bject eli gi bilit y.  A b n or m alities n ote d 
after st u d y tre at m e nt s h o ul d be d oc u me nte d as A Es.
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
I n vesti g at or Si g n at ure D ateTitle  D o c i d  
[ADDRESS_1103669] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 9 4 of 9 6P A R T 2: C o m plete at D a y 7, D a y 1 4 , M o nt hs 1 a n d 6/ E T
N ot d o n e       Pr o vi d e d et ails: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
After q uesti o ni n g t he s u bject a b o ut t heir ge neral healt h a n d perf or mi n g Part 1, deter mi ne if t here are a n y cli nic all y 
si g nific a nt a b n or malities t h at ma y s u g gest l ocal or re m ote s prea d of t o xi n effect.
- L ocal S prea d of T o xi n Effect refers t o effects i n areas a djace nt t o t he treat me nt area ( e. g., l o wer fr o ntalis or
me dial part of te m p oralis).
- Re m ote S prea d of T o xi n Effect refers t o effects i n ot her b o d y parts, n ot a djace nt t o t he treat me nt area, w he n 
effect ca n o nl y be attri b ute d t o t he t o xi n a n d t here is n o o t her me dic all y s o u n d c a use.
- Deter mi ne if t he e ve nt is cli nicall y si g nifica nt ( i.e., wo ul d affect s u bject safet y, c o nf o u n d t he st u d y data, or 
re q uires me dical treat me nt) a n d d oc u me nt o n t he s o urce d oc u me nt.
Please refer t o t he list of re m ote s prea d of t o xi n e ve nts (A p pe n di x 7 ) w hile d oi n g cli nical e val uati o ns base d o n s u bject’s 
s y m pt o ms a n d si g ns. Directe d q uesti o ni n g a n d e xa mi nati o n will t he n be perf or me d as a p pr o pr iate. If ye s, please 
descri be.
P art 2 E x a m i n ati o n N o Yes * ( pr o vi de det ails)
T ar gete d P h ysic al E x a mi n ati o n of F ace a n d 
Nec k t o E v al u ate L oc al S pre a d of T o xi n 
Effect
 L ocal s prea d of t o xi n effect e ve nt(s) 
o bser ve d?
Ge ner al P h ysic al E x a mi n ati o n t o E v al u ate 
t he R e m ote S pre a d of T o xi n Effect
 Re m ote s prea d of t o xi n effect e ve nt(s) 
o bser ve d? 
*  A b n or m alities s h o ul d be d oc u m e nte d as A E.
A d diti o n al c o m me nts f or F oc use d P h ysic al E x a m: 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
I n vesti g at or Si g n at ure D ateTitle  D o c i d  
[ADDRESS_1103670] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 9 5 of 9 6A p pe n di x 7 A d verse E ve nts P ote nti all y S u g gesti ve of Re m ote S pre a d of T o xi n
T he f oll o wi n g a d verse e ve nts ma y p ote ntiall y  be s u g gesti ve of re m ote s prea d of t o xi n (base d o n F D A 
G ui da nce f or I n d ustr y: U p per Facial Li nes: De vel o pi n g B ot uli n u m T o xi n Dr u g Pr o d ucts; A u g ust 
2 0 1 4).[ADDRESS_1103671] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
C O N FI D E N TI A L
Pa ge 9 6 of 9 6SI G N E D A G R E E M E N T O F T H E C LI NI C A L S T U D Y P R O T O C O L
C T N: 4 3 Q M 1 9 0 2
C S P title: A M ultice nter, Ra n d o mize d, D o u ble- Bli n d, Place b o -C o ntr olle d 
St u d y  to E val uate t he Efficac y  an d Safet y of Q M 1 1 1 4 -D P f or t he 
Treat me nt of M o derate t o Se vere Lateral Ca nt hal Li nes a n d Gla bellar 
Li nes Al o ne or i n C o m bi nati o n ( R E A D Y- 3)
I, t he u n dersi g ne d, ha v e rea d a n d u n dersta n d t he C S P s pecifie d a b o ve, a n d a gree o n t he c o nte nts. 
T he C S P, t he cli nical trial a gree me nt ( C T A) a n d t he a d diti o nal i nf or mati o n gi ve n i n t he 
I n vesti gat or’s Br oc h ure (I B) will ser ve as a basis f or c o -o perati o n i n t his st u d y .
Pri nci p al I n vesti g at or
Pri nte d na me Si g nat ure Date
St u d y ce nterTitle  D o c i d  
[ADDRESS_1103672] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
Si g n p a g e: 1 of 1SI G N A T U R E S  PA G E
D at e Si g n e d b y
2 0 2 0- 0 6- 0 8 1 3: 1 3
J u stifi c ati o n A p pr o v e d b y T e c h ni c al E x p ert
2 0 2 0- 0 6- 0 8 1 3: 4 7
J u stifi c ati o n A p pr o v e d b y T e c h ni c al E x p ert
2 0 2 0- 0 6- 0 8 1 5: 0 5
J u stifi c ati o n C o m pil e d b y
2 0 2 0- 0 6- 0 9 0 7: [ADDRESS_1103673] u d y Pr ot oc ol - Q M 1 1 1 4 -  L C L a n d G L
M A- 4 0 3 7 1   Effecti ve dat e:   Versi o n: Eff e cti v e  2 0 2 0- 0 6- 0 9 0 7: 0 2 4. 0
  Pri nt date:  2 0 2 0- 0 6- 0 9 0 7: 1 3
P P D
P P D
P P D
P P D